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"Rabbit's clever," said Pooh thoughtfully.
"Yes," said Piglet, "Rabbit's clever."
"And he has Brain."
"Yes," said Piglet, "Rabbit has Brain."
There was a long silence.
"I suppose," said Pooh,
"that that's why he never understands anything."
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9ABSTRACT
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL) is the most common hereditary vascular dementia.
CADASIL is a systemic disease of small and medium-sized arteries although the
symptoms are almost exclusively neurological, including migraineous headache, recurrent
ischemic episodes, cognitive impairment and, finally, subcortical dementia. CADASIL is
caused by over 170 different mutations in the NOTCH3 gene, which encodes a receptor
expressed in adults predominantly in the vascular smooth muscle cells. The function of
NOTCH3 is not crucial for embryonic development but is needed after birth. NOTCH3
directs postnatal arterial maturation and helps to maintain arterial integrity. It is involved
in regulation of vascular tone and in the wound healing of a vascular injury. In addition,
NOTCH3 promotes cell survival by inducing expression of anti-apoptotic proteins.
NOTCH3 is a membrane-spanning protein with a large extracellular domain (N3ECD)
containing 34 epidermal growth factor-like (EGF) repeats and a smaller intracellular
domain with six ankyrin repeats. All CADASIL mutations are located in the EGF repeats
and the majority of the mutations cause gain or loss of one cysteine residue in one of
these repeats leading to an odd number of cysteine residues, which in turn leads to
misfolding of N3ECD. This misfolding most likely alters the maturation, targetting,
degradation and/or function of the NOTCH3 receptor. CADASIL mutations do not seem
to affect the canonical NOTCH3 signalling pathway. The main pathological findings are
the accumulation of the NOTCH3 extracellular domain on degenerating vascular smooth
muscle cells (VSMCs), accumulation of granular osmiophilic material (GOM) in the
close vicinity of VSMCs as well as fibrosis and thickening of arterial walls. Narrowing of
the arterial lumen and local thrombosis cause insufficient blood flow, mainly in small
arteries of the cerebral white matter, resulting in tissue damage and lacunar infarcts.
CADASIL is suspected in patients with a suggestive family history and clinical picture as
well as characteristic white matter alterations in magnetic resonance imaging. A definitive
verification of the diagnosis can be achieved by identifying a pathogenic mutation in the
NOTCH3 gene or through the detection of GOM by electron microscopy.
To understand the pathology underlying CADASIL, we have generated a unique set of
cultured vascular smooth muscle cell (VSMC) lines from umbilical cord, placental,
systemic and cerebral arteries of CADASIL patients and controls. Analyses of these
VSMCs suggest that mutated NOTCH3 is misfolded, thus causing endoplasmic reticulum
stress, activation of the unfolded protein response and increased production of reactive
oxygen species. In addition, mutation in NOTCH3 causes alterations in actin cytoskeletal
structures and protein expression, increased branching and abnormal node formation.
These changes correlate with NOTCH3 expression levels within different VSMCs lines,
suggesting that the phenotypic differences of SMCs may affect the vulnerability of the
VSMCs and, therefore, the pathogenic impact of mutated NOTCH3 appears to vary in the
arteries of different locations. Furthermore, we identified PDGFR-b as an immediate
downstream target gene of NOTCH3 signalling. Activation of NOTCH induces up-
regulation of the PDGFR-b expression in control VSMCs, whereas this up-regulation is
impaired in CADASIL VSMCs and might thus serve as an alternative molecular
mechanism that contributes to CADASIL pathology.
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In addition, we have established the congruence between NOTCH3 mutations and
electron microscopic detection of GOM with a view to constructing a strategy for
CADASIL diagnostics. In cases where the genetic analysis is not available or the
mutation is difficult to identify, a skin biopsy is an easy-to-perform and highly reliable
diagnostic method. Importantly, it is invaluable in setting guidelines concerning how far
one should proceed with the genetic analyses.
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REVIEW OF THE LITERATURE
1 INTRODUCTION
Stroke is the cause of 9% of all deaths worldwide and it is the second most common cause
of death after ischemic heart disease (Donnan et al. 2008). Stroke is classified as being
ischemic if the primary insult is an occlusion of a blood vessel, or hemorrhagic if the
primary cause is rupture of a blood vessel wall and extravasation of blood. Ischemic
strokes are far more common, covering about 80% of all strokes (Donnan et al. 2008).
The reduction in cerebral blood flow (CBF) in most ischemic cases is caused by occlusion
of a cerebral artery either by an embolus or by a local thrombosis. The focal impairment
of CBF restricts the delivery of oxygen and glucose to the brain tissue, and causes energy
depletion which results in a failure to maintain the ionic gradient across the cell
membrane, and harmful lactacidosis. This leads to dysfunction of calcium channels with
subsequent release of glutamate and further exacerbation of cytoplasmic Ca2+ overload. A
series of deleterious processes is initiated, including activation of degradative enzymes
and generation of free radicals which result in necrotic cell death followed by
inflammatory changes, or trigger apoptosis with delayed cell death. The final result is
hypoxic-ischemic tissue damage, with consequent neurological deficits, for example
different types of strokes or cognitive impairment which may progress to dementia
(Dirnagl et al. 1999).
Vascular dementia (VaD) is the second most common form of dementia after Alzheimer's
dementia. VaD is severe impairment of cognitive functions due to acquired or hereditary
vascular diseases. VaD can be caused by multiple infarcts, strategic infarcts, small-vessel
disease, hypoperfusion injury, haemorrhage and other as well as combined vascular
pathogenetic mechanisms (Kalimo 2005). Gene defects causing hereditary VaD can affect
either the blood vessels or anticoagulative/procoagulative factors in blood, both leading to
severe circulatory disturbances which cause neural tissue necrosis. The cognitive
impairment of VaD differs from that in “classic” dementia. In VaD, executive functions
are much more severely impaired than memory, and the symptoms usually appear
stepwise due to recurrent infarctions that cause destruction of the tissue in the affected
vascular territory (Kalimo 2005).
A vascular dementing disease was described in the literature during the years 1955 to
1993 in several European families with similar clinical and pathological findings but
under a number of different names, including hereditary Binswanger´s disease (van
Bogaert 1955), hereditary multi-infarct dementia (Sourander and Wålinder 1977), chronic
familial vascular encephalopathy (Stevens et al. 1977) and familial disorder with
subcortical ischemic strokes, dementia and leukoencephalopathy (Mas et al.. 1992). In the
1990s, a similar vascular dementing disorder was diagnosed in several French families.
This disease was linked to chromosome 19 and the acronym CADASIL, highlighting the
main characteristics of the disease, was proposed for this disease (Tournier-Lasserve et al.
1993). A major breakthrough was achieved in 1996 when the defective gene was
demonstrated to be NOTCH3 (Joutel et al. 1996) and a year later the stereotypic mutations
were described in detail (Joutel et al. 1997).
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2 CADASIL
Cerebral Autosomal Dominant Artheriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL) is the most common hereditary cerebrovascular
dementia. The first manifestation of the disease is often migraine, which may begin even
before the age of ten years. More severe symptoms, transient ischemic episodes and
recurrent strokes, appear usually between 30 and 50 years of age. Although the symptoms
are almost exclusively neurological, the arteriopathy in CADASIL is systemic. Granular
osmiophilic material (GOM), pathognomonic for CADASIL, accumulates in the close
vicinity of the degenerating vascular smooth muscle cells (VSMC) in small and middle-
sized arteries throughout the body. Degeneration of the VSMCs, accumulation of GOM
and the overproduction of collagen leads to gradual fibrotic thickening and luminal
narrowing of penetrating cerebral arteries. The reduction in the cerebral blood flow (CBF)
finally causes multiple lacunar infarcts, which lead to cognitive deficits and dementia
(Kalimo et al 2008).
CADASIL is caused by missense mutations or small deletions in the NOTCH3 gene
(Joutel et al. 1996), which encodes a large type I transmembrane receptor. Mutations lead
to a gain or loss of one or three cysteine residues in one of the 34 epidermal growth
factor-like (EGF) repeats in the extracellular domain of the NOTCH3 receptor (N3ECD)
(Joutel et al. 1997). The function of NOTCH3 is important in maintaining the phenotypic
stability of VSMCs, and it is needed for arterial maturation after birth (Wang et al. 2008).
In adults, NOTCH3 is expressed almost exclusively in VSMCs, and it may also promote
cell survival by inhibiting apoptosis. The molecular mechanisms which lead to
characteristic vascular pathology of CADASIL are still largely unclear. CADASIL is
slowly progressive and leads to death within a mean of 23 years after symptoms have
occured (Dichgans et al. 1998).
2.1 Epidemiology
Stroke is one of the most common causes of premature death in Western countries.
Strokes at a young age are rare and thus provide a powerful reason for seeking a specific
cause. In one study, where 218 patients were screened for CADASIL mutations, one out
of nine (11 %) suffered from CADASIL in a group of patients aged under 50 years with
lacunar infarcts and leukoaraiosis. The same percentage in a group including somewhat
older patients, aged under 65 years, was only one out of 48 (2%) (Dong et al. 2003).
CADASIL has been reported worldwide in all ethnic groups. The number of CADASIL
families is steadily increasing with better knowledge of its clinical picture and improved
diagnostic examinations. In Finland, the prevalence is very similar to that reported from
other countries (Markus et al. 2002; Razvi et al. 2005); the prevalence of genetically
verified patients is about two per 100 000 and the estimated prevalence based on family
history at least four per 100 000 (30 families, over 200 patients) (Kalimo et al. 2008).
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2.2 Clinical characteristics
The four major symptoms of CADASIL in the order of onset are (1) migraine with aura,
(2) ischemic episodes (transient or strokes), (3) psychiatric symptoms and, finally, (4)
vascular cognitive impairment and subcortical dementia. Because migraine is common as
an independent disease, the age of onset is usually given based on the first ischemic
attack. The age at the first ever stroke varies greatly, from 25 to 70 years.
Migraineous headache is a common symptom of CADASIL, it occurs in up to 60% of
patients of whom in 22-87% it is associated with aura. The migraine attacks may begin
even before the age of 10 years, but more commonly during the third or fourth decade
(Chabriat et al. 1995; Dichgans et al. 1998; Vahedi,et al. 2004). The most common
manifestation (85%) in symptomatic CADASIL patients is the occurence of recurrent
ischemic insults of variable severity (Chabriat et al. 1995; Dichgans et al. 1998). The first
insults are often transient ischemic attacks (TIA) with rapid recovery. Most commonly,
the strokes are focal (lacunar) and located in the periventricular areas, deep white matter
and in basal ganglia (Chabriat et al. 1995). The mean age at the first ever stroke is 45
years, although there is a great variation even within the same family (Chabriat et al.
1995; Dichgans, et al.et al. 1998), and even between monozygotic twins (Mykkänen et al.
2008).
20-30% of CADASIL patients suffer from mood disturbances. The most common
disturbance is depression (Chabriat et al. 1995; Dichgans et al. 1998; Kalimo et al. 2002).
In addition, some other disturbances, such as psychosis, paranoia, agitation and
aggression, dysthymia and emotional lability have been described, although their
connection to CADASIL has not been verified (Chabriat et al. 2007; Verin et al. 1995;
Valenti et al. 2008).
As the disease progresses, recurrent ischemic episodes damage cerebral tissue to an
increasing extent, leading to cognitive decline predominantly affecting frontal lobe
functions. The decline is already detectable in neuropsychological tests before
symptomatic ischemic episodes (Amberla et al. 2004). The patients have impaired
working memory, executive and organizing functions, poor concentration and general
mental and psychomotor slowing (Amberla et al. 2004). With the progression of the
disease other cognitive functions, mainly tasks involving frontal lobes and memory are
affected, leading to a subcortical type of vascular dementia (Amberla et al. 2004).
Cognitive decline becomes clinically manifest between 40 and 70 years of age and about
80% of the CADASIL patients have become demented by the age of 65 years. CADASIL
progresses slowly and leads to death within a mean of 23 years after the symptoms have
occurred (Dichgans et al. 1998). The oldest known CADASIL patient has been a Finnish
female, who died at the age of 96 years after a 28 year-long course of disease
2.3 Imaging findings
In magnetic resonance imaging (MRI), signal abnormalities are detected in both
symptomatic and asymptomatic patients, and the degree of the microstructural alterations
correlates with the severity of the clinical status. MRI signal abnormalities are mainly
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located in the subcortical regions whereas cortical and cerebellar lesions are rare in
CADASIL. T2-weighted MRI (T2wMRI) hyperintensities are characteristic for
CADASIL and are detectable within subcortical regions in the white matter and more
frequently in the periventricular white matter, deep white matter and basal ganglia
(Chabriat et al. 1998). A marked increase in water diffusivity is detected in the diffusion
tensor MRI, not only in the regions appearing hyperintense on T2wMRI, but also in
normal-appearing white matter, indicating loss of anisotropy and suggesting
microstructural changes with enlargement of the extracellular space and demyelination of
the nerve fibres (Chabriat et al. 1999). In symptomatic patients, who have already
experienced strokes, T1-weighted MRI detects small lacunar infarcts which are most
commonly located in cerebral white matter and deep grey matter. CADASIL patients also
have an increased frequency of cerebral microbleeds (Lesnik Oberstein et al.  2001).
Microbleeds are most often located outside the T2wMRI hyperintense areas, indicating
that microbleeds are an independent manifestation of the angiopathy (Dichgans et al.
2002).
2.4 Circulatory disturbances
MRI bolus tracking and positron emission tomography demonstrated that CADASIL
patients have reduced CBF. The reduction of CBF in the white matter already appears at
the presymptomatic stage and becomes clearer after the age of 30 years, along with an
increased severity of the disease (Tuominen et al.  2004). CBF and the cerebral blood
volume (CBV) are significantly decreased, particularly within the areas appearing
hyperintense in T2wMRI. This reduction is more severe in demented than in non-
demented patients (Chabriat et al. 2000; Bruening et al.  2001). An acetazolamide-
induced increase in CBF and CBV in the cortex and white matter was lower in T2w
hyperintense areas in patients than in control subjects, which suggests that CADASIL
patients have a reduced hemodynamic reserve (Chabriat et al.  2000). CADASIL patients
have a prolonged arteriovenous cerebral transit time, which represents the time that a
contrast agent needs to pass from a cerebral artery to its corresponding vein, and reflects
microvascular changes in CADASIL (Liebetrau et al. 2002). In addition, CADASIL
patients have an impaired endothelium-dependent vasodilation and reduced blood flow in
the forearm resistance arteries, whereas large conduit arteries do not show any difference
compared to controls. (Stenborg et al. 2007; Peters et al. 2008).
2.5 Pathological characteristics
In concordance with the MRI findings, in a post mortem CADASIL brain, there can be
seen multiple lacunar infarcts in the white matter and deep grey matter, whereas the
cerebral cortex is remarkably well preserved. Lacunar infarcts are also relatively common
in the brain stem (Ruchoux et al.  1997; Kalimo et al. 2002). Pathological changes are
present in all arteries of the body and in some veins. Walls of small and middle-sized
arteries are thickened mainly because of excessive production of extracellular matrix
(ECM) proteins, like fibronectin, vimentin and type I collagen (Ruchoux et al. 1997;
Kalimo et al. 2002). N3ECD accumulates on the surface of VSMCs (Joutel et al. 2000),
which are degenerating as demonstrated by decreased immunostaining of smooth muscle
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a-actin (a-SMA), desmin and myosin. In the arterial wall, the subendothelial space is
enlarged and the degenerating VSMCs appear irregularly shaped as they have lost their
intercellular connections (Ruchoux et al. 1997). As a striking feature of CADASIL, GOM
accumulates on VSMCs (Baudrimont et al. 1993; Ruchoux et al. 1995).
2.5.1 GOM
In the arterial wall, in the media tunica, there is an accumulation of GOM, which is
negative in both histological (e.g. Congo red and thioflavin) and immunohistochemical
stainings for different amyloid angiopathies (Ruchoux et al. 1997; Ragno et al. 1995).
GOM is detected in the close vicinity of VSMCs, often in small indentations of plasma
membrane or free in the extracellular space within the basal lamina, which is usually
irregularly thickened (Figure 1.). The indentations are often covered with caveolar
structures, but as caveolae are common structures of VSMCs, their pathological
significance is unclear. GOM deposits are of variable size, ranging from 0.2 µm to 0.8
µm, and are composed of 10-15 nm granules (Ruchoux et al.. 1997). GOM can appear in
electron microscopy (EM) as evenly electron dense or, as often, denser on the side which
is towards the VSMC membrane and sparser on the other side. The exact composition of
GOM has not been fully identified, but N3ECD is a component of GOM as demonstrated
by immunoelectron microscopy (Ishiko et al. 2006). Moreover, with confocal
microscopy, N3ECD immunoreactivity can be seen as dot-like accumulations on the
Figure 1. GOM. Electron micrograph of an artery from a CADASIL patient’s skin biopsy.L= arterial
lumen; E= Endothelial cell; VSMC= Vascular smooth muscle cell. Four GOMs are shown with
arrowheads and widend subendothelial space is indicated with asterisks.
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arterial wall, in concordance with the appearance of GOM deposits in the EM (Kalimo et
al. 2008). GOM has not been detected in any other disease entity, and the detection of
GOM is considered a possible diagnostic tool. The degeneration of VSMCs and the
accumulation of GOM begin early. The morphological changes in arteries and the
accumulation of GOM are already detectable before the age of 20 (Kalimo  et al. 2008).
2.5.2 Vascular differences
The most severely affected arterioles are the small (<130 mm external diameter)
penetrating arteries in the cerebral white matter where the majority of lacunar infarcts also
occur. These arteries have a highly significant increase in the sclerotic index and they are
stenosed with significantly smaller mean internal (luminal) diameters. Finally, these
arterioles may become severely obliterated or thrombosed to give rise to lacunar infarcts
(Miao et al. 2004). Interestingly, in the other region of the brain where lacunar infarcts
occur in CADASIL, the deep grey matter of basal ganglia (nucleus lentiformis), the small
arteries are not stenosed as in the white matter even though their walls are thickened. This
suggests a different, probably hemodynamic pathogenesis for the lacunar infarcts in the
basal ganglia (Miao et al. 2006). In the cerebral cortex, the small arterioles are also
thickened and their lumina somewhat narrowed, but to a considerably lesser extent than in
the white matter, thus explaining the absence of cortical infarcts (Miao et al. 2004). These
findings emphasise the fact that there is a fundamental difference between the cortical and
white matter arteries
2.6 Genetics
The gene causing CADASIL, NOTCH3, is located in chromosome 19, in 19p13.1-13.2
(Joutel et al. 1996; Tournier-Lasserve et al. 1993). Today, over 170 mutations causing
CADASIL have been identified (Supplemental Table in Study IV). A great majority of
the mutations are point mutations causing an amino acid substitution involving a cysteine
residue. The gain or loss of one cysteine residue leads to an uneven number of cysteines
in one of the 34 EGF repeats in the N3ECD (Joutel 1997). In addition, eight different
deletions have been described, each of which causes a loss of either one or three cysteine
residues, thus resulting in an uneven number of cysteines (Supplemental Table in Study
IV). About 62% of reported mutations cluster at the N terminus of the NOTCH3 gene in
exons 3, 4, 5 and 8 that encode the five first EGF repeats of the N3ECD (Kalimo et al.
2008).
Practically all patients are heterozygous for the NOTCH3 mutation, with the exception of
two reported patients who have been diagnosed to be homozygous, one for the c.397C>T
mutation which causes a relatively common p.Arg133Cys substitution (Tuominen et al.
2001) and one for the c.1732C>T mutation which causes p.Arg578Cys substitution (Liem
et al. 2008). The phenotype of the homozygous patient carrying p.Arg133Cys mutation
was relatively severe but still within the normal spectrum. A heterozygous family member
of this patient has a similarly severe phenotype. The other homozygous patient carrying
p.Arg578Cys substitution had a very mild phenotype and did not differ significantly from
that of patient’s heterozygous relative. This suggests that CADASIL follows the classic
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definition of the dominant pattern of inheritance (Tuominen et al. 2001; Liem et al. 2008).
Genetic modifiers affecting the severity of the phenotype and disease progression are still
unknown and there is no correlation of ischemic brain lesions with specific mutations
(Opherk, et al. 2006). Eight CADASIL patients/families have been reported with
NOTCH3 mutation which does not involve a cysteine (Okeda, et al. 2002; Uchino, et al.
2002; Mazzei, et al. 2004; Kim, et al. 2006; Ferreira, et al. 2007a; Ferreira, et al. 2007b;
Mizuno, et al. 2008; Scheid, et al. 2008). Interestingly, a non-cysteine mutation in exon
25 (p.Leu1515Pro) of NOTCH3 was recently shown to cause a small vessel disease
distinct from CADASIL without accumulation of N3ECD or GOM on the VSMCs. This
mutation causes NOTCH3 to be constitutively active (Fouillade, et al. 2008).
2.7 NOTCH3 protein
NOTCH3 is a member of the NOTCH receptor family, which in mammals has four
members (NOTCH1-4). NOTCH signalling is evolutionarily conserved and there are
orthologous genes with a high degree of homology from nematodes to man (Artavanis-
Tsakonas et al. 1999).
2.7.1 Structure
The human NOTCH3 gene has 33 exons that code for a 2321 amino-acid-long NOTCH3
receptor with a single membrane-spanning domain (Figure 2) (Joutel et al. 1996). The N-
terminal extracellular part of the receptor (210 kilodaltons) contains 34 EGF repeats, of
which sixteen have a calcium binding site. The EGF repeat is an abundantly occurring,
independently folding protein module that is thought to play a general role in extracellular
events such as adhesion, coagulation, and receptor-ligand interactions. Each EGF repeat
is approximately 40 amino acids long and contains six cysteine residues, which form
three sulphur bridges in a very organized way (organized in a 1-3, 2-4, 5-6 arrangement)
as the protein domain is folded (Downing et al. 1996). The folded domain contains two
anti-parallel b sheets stabilized by three disulphide bonds (Whiteman et al. 2006a). The
ligand recognition site (LRS) of NOTCH3 is located at the calcium binding EGF repeats
10 and 11. The EGF repeats are followed by three cysteine-rich lin-12/notch repeats, a
region present only in notch-related proteins and a domain which appears to negatively
regulate receptor activation (Weinmaster 1997). The membrane-spanning domain of
NOTCH3 is only 21 amino acids long. The NOTCH3 intracellular domain (N3ICD, 97
kilodaltons) contains a RBP-Jk-associated molecule domain in the juxtamembrane part
followed by six putative ankyrin repeats, of which only five are likely to adopt an ankyrin
fold. The RBP-Jk-associated molecule domain and ankyrin repeats serve as interaction
interfaces with other proteins. The C-terminal region contains a PEST motive, which
directs N3ICD to rapid proteasomal degradation (Rogers et al. 1986) and leads to an
attenuation of NOTCH-induced signalling
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2.7.2 Ligands
NOTCH3 ligands belong to the Delta/Serrate/Lag-2 (DSL) family (Delta and Serrate from
Drosophila and Lag-2 from C. elegans). Five homologous ligands have been identified in
mammals: DELTA-1 (Bettenhausen et al. 1995), DELTA-3 (Dunwoodie et al. 1997),
DELTA-4 (Shutter et al. 2000), JAGGED-1 (Serrate in invertebrates) (Lindsell et al.
1995) and JAGGED-2 (Shawber et al. 1996). The molecular structure of DSL ligands
resembles that of NOTCH. They are transmembrane proteins with large extracellular
domains containing several EGF repeats. Unlike NOTCH, they all possess a
characteristic, N-terminal DSL domain which is involved in cell-cell signalling
interactions. Similarly to the counterparts in drosophila, the human JAGGED-1 and
JAGGED-2 are much larger than the DELTA-like proteins and contain twice the number
of EGF repeats (Weinmaster 1997). DELTA-4, JAGGED-1 and JAGGED-2 expression is
detected in embryonic mouse arteries, thus they are putative ligands for NOTCH3 in vivo
(Villa et al. 2001, Prakash et al. 2002). Mutations in the NOTCH ligand JAGGED-1
cause Alagille syndrome, which is a dominantly inherited multisystem disorder involving
vascular abnormalities in the liver, heart, eyes, face, and skeleton (Kamath et al. 2004).
2.7.3 Receptor maturation and signaling
Most of the studies investigating the molecular mechanisms of receptor maturation,
ligand binding and transcription have been carried out in NOTCH1 receptor and/or model
Figure 2. NOTCH3 structure
A precursor protein is cleaved in the Golgi
apparatus by a furin at site S1 to produce a
bipartite molecule, composed of an extracellular
domain (N3ECD) and a transmembrane-
intracellular domain (N3TMICD). N3ECD
contains 34 EGF repeats. The ligand recognition
site (LRS) is located in EGF repeats 10 and 11.
EGF repeats are followed by three Lin12/ notch3
repeats. NOTCH3 has a single pass
transmembrane domain followed by N3ICD
containing 6 putative ankyrin repeats of which
only five are likely to adopt an ankyrin fold. In
the C terminus, NOTCH has a PEST motive,
which directs proteins to rapid proteasomal
degradation. Ligand binding induces two
proteolytic cleavages. First, NOTCH3 is cleaved
by TACE at site S2, generating a truncated
N3TMICD which is subsequently cleaved at site
S3 by g-secretase releasing N3ICD. N3ICD
enters the nucleus, binds to transcription factor
RBP-Jk (=CSL) and regulates transcription. The
Non-CADASIL small vessel disease is caused by
the p.Lau1515Pro mutation leading to
constitutively active NOTCH3 (activating
mutation).
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organisms Drosophila and C. elegans. However, the molecular mechanism of these
events is proposed to be similar for all NOTCH receptors and for higher organisms,
including humans.
Receptor maturation
NOTCH is transcribed as a single polypeptide chain, and after translation and insertion to
the endoplasmic reticulum (ER) membrane it undergoes glycosylation events in the EGF
repeats (Panin et al. 2002). Several NOTCH EGF repeats are O-glycosylated and O-
fucosylated, in which O-fucose is added by O-fucosyltransferase 1. The
glycosyltranferase fringe catalyses the elongation of the O-linked fucose on the EGF
repeats of NOTCH (Moloney et al. 2000b; Moloney et al. 2000a). The expression of O-
fucosyltransferase 1 has been shown to inhibit the response to the Serrate (JAGGED)
ligand and potentiate the response to the DELTA ligand (Panin et al. 1997). The
glycosylated NOTCH is transported via the secretory pathway to the Golgi complex,
where it is enzymatically cleaved by a furin-like convertase (S1 cleavage, Figure 2). The
S1 cleavage appears to be an important regulator of the further transport of NOTCH. The
two cleavage products are held together by metal ions (Ca2+), generating a bipartite
protein which is inserted into the plasma membrane (Blaumueller et al. 1997).
Signalling
Ligand binding dissociates the NECD from the rest of the receptor (Figures 2 and 3). The
DSL ligand-NECD complex is internalized via the clathrin-dependent pathway into
ligand-expressing cells and directed into the endosome (Nichols et al. 2007a). In the
endosome, the DSL ligand may be dissociated from the NECD, allowing it to be recycled,
while the NECD is directed into lysosomes and degraded. The DSL ligand-NECD
transendocytosis triggers two proteolytic cleavages. NOTCH is cleaved by an ADAM
family protease, the TNFa-converting enzyme (TACE) at the S2 cleavage site that is
located 12 amino acids external to the transmembrane domain (Brou et al. 2000). The S2
cleavage results in a truncated transmembrane-intracellular domain (NTMICD) receptor
which is susceptible to the third S3 cleavage. It is suggested that the remaining NTMICD
is mono-ubiquitinated to an intracellular lysine residue close to the juxtamembrane region
and then endocytosed (Gupta-Rossi et al. 2004). In the endocytotic vesicle, NTMICD is
cleaved again at the S3 site located within the plasma membrane by g-secretase (Mumm
et al. 2000). However, the active enzyme, which is a complex of presenilin-1, nicastrin,
Aph-1 and Pen-2, has also been isolated from the plasma membrane and therefore the
exact cellular location of the S3 cleavage is still unclear (Chyung et al. 2005). g-secretase
also cleaves amyloid-b precursor proteins and is involved in Alzheimer disease
pathology. The S3 cleavage releases the NOTCH intracellular domain (NICD), which
then translocates to the nucleus and binds to a J k-recombination signal-binding protein
(RBP-Jk), which is a deoxyribonucleid acid (DNA)-binding protein belonging to the
CBF1 (mammalian), Supressor of hairless (Drosophila) and Lag-1 (C. elegans) (CSL)
family of transcriptional regulators (Artavanis-Tsakonas et al. 1999). In the absence of
NICD, the RBP-Jk binds to ubiquitous co-repressor proteins and histone deacetylases and
represses transcription of target genes. In the nucleus, NICD replaces the histone
deacetylase-co-repressor complex from the RBP-Jk and forms a transcription-activating
complex to which it further recruits co-activator proteins, such as the mastermind-like
protein and the histone acetyltransferase and leads to transcriptional activation of NOTCH
target genes HEY and HES (Figure 3) (Gridley 2007; Ilagan et al. 2007).
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The HEY and HES genes are the best characterized direct downstream genes of NOTCH
signalling. These genes contain a CSL-binding site in their promoter regions. All HEY
and HES genes encode basic helix-loop-helix transcription factors, and they act as
transcriptional repressors blocking the expression of differentiation-promoting tissue-
specific genes (Gridley 2007). Even though CSL-binding sites have been identified in
many genes, only a few have been experimentally shown to be direct NOTCH
downstream genes (Kovall 2007). Considering the importance of NOTCH3 function in
vascular development and maintaining the VSMC phenotype, it is very likely that there
are additional genes directly regulated by NOTCH3.
The NICD interacts with other signalling cascades in the cell, such as the Transforming
Growth Factor beta (TGF-b) and integrin activation. N4ICD has been shown to directly
interact with TGF-b downstream signalling proteins smad3 and 4 and attenuate the
activation of promoters that contain a smad-binding element (Sun et al. 2005).
Constitutively active N4ICD enhances ?1 integrin-mediated adhesion of cells to collagen
and thus inhibits cell migration through the collagen matrix (Leong et al. 2002). In
addition, NOTCH1 signalling activates b1 integrin and increases cell adhesion to
fibronectin in a R-Ras-dependent way (Hodkinson et al. 2007).
2.7.4 NOTCH signalling is regulated by endocytosis
Endocytosis
Endocytosis is an important membrane trafficking event and it is involved in many of the
cellular functions, such as intake of nutrients, antigen presentation and regulation of cell
surface receptor expression. Internalization of cell surface receptors is associated with
signal attenuation, down regulation of cell-cell signalling and signal transduction.
There are two major receptor-mediated endocytosis mechanisms: caveolar and clathrin-
mediated pathways. In the clathrin-mediated pathway, vesicles budding from the plasma
membrane are coated with clathrin and assembly protein 2, of which the assembly protein
links receptors to clathrin. Pinching off clathrin-coated vesicles requires additional
adaptor proteins, such as epsin and dynamin. Receptors that are directed to clathrin-
mediated endocytosis have intracellular sorting signals which can be intrinsic for the
receptor or added post-translationally, like mono-ubiquitination. The E3 ubiquitin ligases
add mono-ubiquitin to one or multiple lysine residues of transmembrane receptors
(d'Azzo et al. 2005). Ubiquitination influences receptor stability, protein-protein
interactions and intracellular localization of molecules. It is a signal for internalization
and targets the modified substrate to endocytic compartments, followed by recycling or
degradation (d'Azzo et al. 2005; Haglund et al. 2003). The endocytosed vesicles are
targeted to early endosomes, which are the major sorting organelles of the cell. These
endosomes mature to become sorting endosomes where the cargo is sorted and targeted
for lysosomal degradation or recycling if deubiquitinated. Cargo destined for degradation
is sorted into multivesicular bodies (late endosomes) that fuse with lysosomes, which
contain a mixture of different proteases. Cargo destined for recycling is sorted in early
endosomes and may be recycled back to the plasma membrane directly or via recycling
endosomes (Wilkin et al.  2005; Le Borgne et al.  2005).
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Role of ligand endocytosis
The activities of NOTCH and DSL ligands are tightly regulated by endocytosis,
membrane trafficking and signalling modulators. Several studies indicate that clathrin-
mediated endocytosis of the ligand is required for NOTCH activation in the signal-
sending cell (Nichols et al. 2007a; Mumm et al. 2000; Struhl et al. 2000; Wang et al.
2004; Parks et al. 2000; Itoh et al. 2003). Endocytosis is suggested to regulate NOTCH
signalling according to two different models (Figure 3) (Wilkin et al. 2005; Nichols et al.
2007b; Chitnis 2006).
The first model suggests that the binding of the ligand to NOTCH and the subsequent
pulling force generated by transendocytosis of the ligand-NECD complex to the ligand-
expressing cell promotes proteolytic cleavage of NOTCH (Wilkin et al. 2005; Le Borgne
et al. 2005; Nichols et al. 2007b). The NECD masks the S2 cleavage site and it is
suggested that the ligand binding physically separates the non-covalently attached NECD
from NTMICD at the Ca2+ bond (Nichols et al. 2007a) and, subsequently, the ligand-
NECD complex is transendocytosed into the ligand-expressing cell (Nichols et al. 2007a;
Parks et al. 2000). The NECD transendocytosis with the ligand does not require
proteolytic activity and, therefore, it is suggested that the physical detachment of the
NECD from the receptor exposes the S2 site of NOTCH3 for the enzyme (Nichols et al.
2007a). Alternatively, the mechanical force associated with ligand-NECD endocytosis
can cause conformational changes in NOTCH that make the S2 cleavage site accessible
for TACE (Chitnis 2006).
In the second model, it is proposed that endocytosis and recycling are needed for
clustering and directing the ligand to an appropriate membrane compartment. This is
necessary to produce an activated and effective ligand (Wilkin et al. 2005; Le Borgne et
al. 2005; Nicholset al. 2007b; Heuss et al. 2008). It has been demonstrated that
ubiquitination and endocytosis enhance the DSL ligand-induced NOTCH signalling
(Parks et al. 2000; Itoh et al. 2003; Heuss et al. 2008) and a soluble pre-clustered DELTA
is a more effective ligand for NOTCH than an unclustered ligand. Therefore, it is
suggested that the ligand endocytosis pre-clusters DSL ligands and makes the ligand
cluster a more effective activator (Hicks et al. 2002). Moreover, it has been demonstrated
that to function efficiently, the DSL ligand requires additional proteins that function in the
clathrin-mediated endocytosis, such as clathrin, dynamin (Seugnet et al. 1997) and epsin
(Nichols et al. 2007a). Ubiquitination of the intracellular domain of DSL ligands by E3
ubiquitin ligases, Mind bomb and Neuralized (Itoh et al. 2003; Lai et al. 2001; Song et al.
2006), directs the DSL ligand to a specific epsin-mediated endocytotic pathway (Wang et
al. 2004). Epsin has an ubiquitin interaction motif, which seems to be required for
NOTCH activation by DELTA. Therefore, it is suggested that the ubiquitin interaction
motifs interact with each other and cluster the ubiquitinated DSL-ligands. This could
generate multiple interaction sites for enhancing signalling activity, especially if NOTCH
is also clustered (Nichols et al. 2007b; Chitnis 2006).
However, ubiquitination appears not to be necessary for the DSL ligand endocytosis, but
is required for the ligand recycling and efficient interaction with NOTCH (Heuss et al.
2008). It is suggested that during endocytosis and recycling, the ligand could undergo
modifications that convert the inactive ligand to its active form, which would make the
interaction with NOTCH more effective. However, the specific molecular modifications
are not well defined (Wang et al. 2004; Heuss et al. 2008).
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These studies indicate that endocytosis and recycling of the ligand might enhance the
association of the ligand with other co-factors and alter the way in which the ligand is
presented to NOTCH. It is not definitively clarified, what the initial signal is for the
ligand to be ubiquitinated and to enter the special endocytic pathway for conversion from
the inactive pre-ligand into the active form, and to be then recycled into the specific lipid
microdomain (Heuss, et al. 2008). Whether an initial interaction between the ligand and
NECD is needed for the ligand-recycling cascade to begin is still unresolved. These two
models of the role of endocytosis in NOTCH signalling do not exclude each other and
thus, it might be that endocytosis is needed for both, to generate an active ligand and to
induce NOTCH cleavage and signalling.
Role of NOTCH endocytosis
A basal level of the cell surface NOTCH and its activity is also regulated by the ubiquitin-
dependent endocytosis, sorting, degradation and recycling. There appears to be a
continuous flux of NOTCH delivery to and endocytotic removal from the plasma
membrane. The endocytosis is suggested to downregulate NOTCH expression on the cell
surface (Wilkin et al. 2005; Nichols et al. 2007b). In mammals, E3 ubiquitin ligases Cbl
and Itch/AIP4 have been associated with NOTCH (Wilkin, et al.et al. 2005; Nichols, et
al.et al. 2007b) and, if the activated DSL ligand does not recognize NOTCH, Itch/AIP4
sorts and directs NOTCH for lysosomal degradation (Chastagner, et al.et al. 2008). In
addition, It is proposed that NOTCH also undergoes clustering to achieve effective
signalling (Nichols et al. 2007a; Nichols et al. 2007b) but whether its endocytosis is
required is not known.
2.7.5 Function
NOTCH signalling influences cell differentiation, proliferation, and apoptotic events at all
stages of development. In addition, NOTCH signalling participates in the development of
the cardiovascular system and vasculature including vasculogenesis, angiogenesis and
differentiation and remodelling of the VSMCs (Wang et al. 2008). The NOTCH
signalling pathway appears to function as a highly organized developmental instrument
that is used for directing cell fate and building an organism.
Figure 3. The proposed NOTCH3 signalling pathway. (A) In the signal-sending cell, membrane
bound DSL ligands are ubiquitinated by E3 ligases named Neuralized and Mind bomb, and endocytosed
to be targeted to a specific recycling pathway. (B) The recycling process converts inactive DSL ligands
to an active form and clusters them to the cell membrane. (C) In the signal-receiving cell, furin-cleaved
bipartite NOTCH3 is targeted to the plasma membrane. If an activated DSL ligand does not recognise
NOTCH3, ubiquitin E3 ligases cbl and Itch/AIP4 ubiquitylate NOTCH3 and direct it for lysosomal
degradation. (D) The binding of the DSL ligand to NOTCH3 initiates transendocytosis of the N3ECD-
DSL complex into the signal-sending cell and the complex is targeted for recycling or degradation. The
pulling force generated by transendocytosis either, (E) induces a conformational change of the NOTCH3
receptor or (F) completely dissociates the extracellular part from the bipartite NOTCH3 at the Ca2+ bond,
exposing the remaining membrane-bound part of NOTCH3 receptor for two proteolytic cleavage events.
First, TACE generates a S2-cleaved fragment (G) which is subsequently cleaved by g-secretase at site
S3. (H) The S3 cleavage generates N3ICD, which translocates to the nucleus, binds RBPJ-k and
activates the expression of target genes. CoR = corepressor; CoA = coactivator. For details, see
paragraph: NOTCH signalling. Most of the proposed mechanisms are demonstrated in studies made with
other NOTCH receptors.
.
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Vascular development
During early mouse embryonic development, NOTCH1, 2 and 3 have quite distinct
expression patterns (Williams, et al.et al. 1995) which are compatible with different
phenotypes that result from the deficiency of these genes. Notch1-deficient mice die in
utero after 11.5 days of gestation due to defects in the vascular development (Swiatek et
al. 1994) and homozygously mutated Notch2 mice die before embryonic day 11.5
(Hamada et al. 1999). However, mice deficient in Notch4 or Notch3 (Notch3-/-) are all
viable and fertile (Krebs et al. 2000; Domenga et al. 2004; Krebs et al. 2003). This
indicates that NOTCH3 and NOTCH4 are not essential during embryonic development.
During postnatal growth, the vasculature matures and the size and transport capacity of
the vasculature expand significantly. Notch3-/- mice develop vascular defects by postnatal
day 28, which demonstrates that NOTCH3 is important for vascular development after
birth (Domenga et al. 2004).
At birth, when the vasculature, the SMC layer in particular, is immature, the arterial
vessels of Notch3-/- mice are indistinguishable from the control littermates (Domenga et
al. 2004). Subsequently, arterial SMCs mature and undergo co-ordinated changes in their
shape and orientation, endowing the arterial vessels with their final appearance by
postnatal day 28. The maturation process is significantly impaired in Notch3-/- mice.
Adult arteries of Notch3-/- mice show structural abnormalities, including enlarged arteries,
a thinner SMC layer and an abnormal SMC shape and size. The elongated SMCs and
clusters of poorly oriented cells around the lumen suggest that the arteries of the Notch3-/-
mice follow a venous rather than an arterial pattern of maturation (Domenga et al. 2004).
In addition, VSMCs of Notch3-/- mice have reduced amounts of several cytoskeletal
components characteristic of mature SMCs, including dense plaques and dense bodies,
and have a reduced amount of the arterial SMC marker protein, smoothelin (Domenga et
al. 2004). Interestingly, there is no difference in the expression of the canonical NOTCH
downstream target genes (Hes1, Hey1, Hey2 and Heyl) between Notch3-/- mice and
control littermates. This data indicates that NOTCH3 regulates arterial differentiation and
maturation of VSMCs after birth. Furthermore, this regulation is mediated by non-
canonical target genes that need to be elucidated.
Adult vasculature
The NOTCH signalling induces SMC differentiation and in the adult NOTCH3 has not
been demonstrated to be expressed in other tissues than VSMCs and pericytes (Joutel et
al. 2000; Villa et al. 2001). The adult VSMCs are not terminally differentiated and they
are able to change their phenotype in response to local environmental demands, including
growth factors, mechanical forces, cell-cell and cell-ECM interactions and inflammatory
mediators. The phenotypic stability is important to preserve the physiological functions of
arteries. In normal physiological conditions, VSMCs maintain a contractile phenotype by
expressing SMC-restricted contractile and cytoskeletal proteins required for the
modulation of arterial tone and vascular homeostasis (Morrow et al. 2005a; Morrow et al.
2005b; Proweller et al. 2005). Smooth muscle myosin heavy chain (SMMHC) (Doi et al.
2006) and a-SMA (Noseda et al. 2006) are NOTCH target genes.
NOTCH3 is involved in wound healing of vascular injuries. In a vascular injury, platelet-
derived growth factor-BB (PDGF-BB) is released and causes downregulation of the SMC
marker genes, including a-SMA and SMMHC, and accelerates VSMC growth and, thus,
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leads to vascular remodelling (Marmur et al. 1992). Within two days after an
experimentally-induced vascular injury, expression of NOTCH3 and its target genes are
downregulated. The expression is again upregulated 7-14 days after the injury compared
to uninjured vessels (Wang et al. 2002; Campos et al. 2002). Angiotensin II is a potent
vasoconstrictor and also involved in vascular injury. Angiotensin II and PDGF treatment
in vitro caused downregulation of NOTCH3 and its target gene expression and an
upregulation of JAGGED1 expression, thus indicating that NOTCH3 is a downstream
mediator of these factors (Campos et al. 2002). Since Pdgf-deficient mice did not have
significant changes in NOTCH3 expression, it seems that NOTCH3 is not under the direct
control of PDGF (Prakash et al. 2002).
Several studies indicate that NOTCH3 signalling promotes cell survival and inhibits
apoptosis. In cell culture experiments, expression of constitutively active N3ICD rescues
VSMCs from apoptosis, promotes VSMC proliferation and inhibits migration (Wang et
al. 2002; Wang et al. 2003; Sweeney et al. 2004). It was demonstrated that the
constitutively active N3ICD in cultured VSMCs increased resistance to Fas ligand-
induced apoptosis (Wang et al. 2002). Activation of Fas by its ligand induces cell death
through an activation of caspase-8 by the adapter protein Fas-associated death domain
protein. Expression of N3ICD results in upregulation of c-Flip, which is a competitive
inhibitor of caspase-8 binding to the Fas receptor complex, thus inhibiting programmed
cell death (Wang et al. 2002). This anti-apoptotic mechanism is independent of the RBP-
Jk activation and is mediated via activation of the MAPK pathway by an unknown cross-
talk mechanism (Wang et al. 2002). In addition, serum deprivation-induced apoptosis in
VSMCs was shown to be inhibited by N3ICD via the RBP-Jk-dependent pathway
(Sweeney et al. 2004). The mechanisms leading from NOTCH3 activation to the
upregulation of survival signals definitely exists, but the pathways leading to the anti-
apoptotic response are still unclear.
Cyclic mechanical strain in vitro induces apoptosis and inhibits proliferation of VSMCs
(Morrow et al. 2005b), and also causes a reduction of NOTCH1 and NOTCH3 expression
with a concomitant increase in the expression of VSMC differentiation markers a-SMA,
calponin, myosin and smoothelin (Morrow et al. 2005a). The mechanical strain therefore
seems to lead to the increased expression of VSMC differentiation markers, resulting in a
more contractile phenotype. The role of NOTCH3 in vasoregulation is strengthened by
the observations made in Notch3-/- mice. These mice have an increased vasodilation
response to shear stress, a reduced vascular tone induced by mechanical strain and a
decreased RhoA activity and myosin heavy chain phosphorylation, suggesting decreased
actin polymerization (de Chantemele et al. 2008). It was further shown that the expression
of constitutively active N3ICD resulted in increased amounts of actin stress fibres, higher
steady state levels of polymerized actin and a higher resistance to actin depolymerization
drugs (Domenga et al. 2004). Therefore, in addition to its role in postnatal vascular
development, NOTCH3 may also play a significant role in determining the adult VSMC
phenotype, regulate actin cytoskeleton dynamics and be involved in the mechanical strain
response in vascular cells facing various environmental demands (Domenga et al. 2004;
Morrow et al. 2005a).
Interestingly, it was demonstrated that in Notch3-/- mice, the area of focal ischemia
induced by middle cerebral artery occlusion was markedly larger than in the wild type
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littermates. The vulnerability to stroke was normalized when the wild type human
NOTCH3 was expressed in these mice (Arboleda-Velasquez et al. 2008). It was therefore
proposed that NOTCH3 defines a pivotal factor of stroke burden by regulating VSMC
function and may thus contribute to maintaining the vascular hemodynamics. These data
lead to a hypothesis that NOTCH3 may serve as a sensor that provides the VSMC with
the ability to rearrange actin in response to mechanical strain (Domenga et al. 2004).
Interestingly, it was recently demonstrated that two ECM proteins, microfibril-associated
glycoprotein (MAGP) -1 and -2 are able to bind and activate NOTCH1 (Miyamoto et al.
2006). There is no corresponding data for NOTCH3. However, if NOTCH3 is able to
interact with ECM proteins, it can act as a sensor or transducer that provides VSMCs with
the ability to respond to mechanical stretching of the vessel wall induced by blood
pressure (Domenga et al. 2004).
2.8 Molecular mechanisms of CADASIL pathogenesis
Relatively little is known about NOTCH3 function in the human adult, and this is
reflected in the knowledge of the molecular mechanisms leading to CADASIL pathology.
Whatever the molecular mechanisms causing the degeneration of VSMCs are, the key
functional consequence is an insufficient blood flow in small cerebral arteries that causes
tissue damage and lacunar infarcts. The destruction of VSMCs is followed by fibrosis
with marked thickening of the walls of small arteries as well as narrowing of the arterial
lumen and stenosis (Miao et al. 2004). The small penetrating white matter arteries may
become completely obliterated by the fibrotic process. Most likely, the final cause of the
lacunar infarcts is, however, thrombosis in the affected arteries. The fibrosis and stenosis
in the penetrating white matter arterioles is significantly more severe than in the cortical
arteries, and the lack of collateral arteries makes the white matter more vulnerable to
reduced blood flow. On the other hand, CBF is under strict autoregulation, and
hemodynamic disturbance due to the rigidity of fibrosed arterioles could lead to white
matter infarcts. Thus, impaired vasodilation of the thick-walled white matter arterioles
may result in focal ischemia due to “stealing” of blood flow from the white matter to the
cerebral cortex, where less severely affected arterioles have a greater capability to dilate.
(Stenborg et al. 2007; Miao et al. 2004).
What are the molecular mechanisms behind these pathological consequences? Several
different hypotheses have been suggested. These include the gain of toxic function
(Donahue et al. 2004), loss of physiological function, “sop up” of the ligand (Spinner
2000), impaired receptor maturation and targeting and the misfolding of the mutated
receptor (Dichgans et al. 2000).
2.8.1 Misfolding
Protein folding
After the translation, the linear amino acid chain is folded to gain a 3-dimensional
structure that forms the functional protein. This is one of the most complex challenges
faced by the cellular protein factory. The majority of the proteins fold in the cytosol
(cytosolic soluble proteins) or in the ER (secreted and membrane proteins). The ER
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contains a wide range of molecular chaperones, folding catalysts and proteins of the ER
quality control, which help in protein folding, to recognize misfolded proteins and target
them for degradation (Sitia et al. 2003). The ER quality control primarily recognizes
structures within the proteins, like hydrophobic patches, immature glycans and unpaired
cysteines (Meusser et al. 2005). A notable series of N-glycosylation and deglycosylation
reactions serve as a timer for glycoprotein folding. This mechanism allows the cell to
eliminate proteins that have not folded correctly even after extensive attempts (Meusser et
al. 2005). The remarkable number of oxidoreductases in the ER suggests that catalysis
and regulation of disulphide bond formation are essential for correct protein folding and,
consequently, without proper disulphide bonds native conformation cannot be attained
(Sitia et al. 2003). During folding, the continuous activity of oxidoreductases ensures that
disulphide bonds remain flexible until folding is completed (Sitia et al. 2003). Proteins
which are recognized as unfolded or misfolded are retained in the ER for further folding
attempts. When a protein is recognized as a terminally misfolded molecule, it is
dislocated through a protein-conducting channel from the ER to the cytosol where it is
ubiquitinated and degraded by the 26S proteasome (Meusser et al. 2005; Goldberg 2003).
The function of the cell relies heavily on the ability to produce correctly folded proteins.
Cells have evolved a mechanism to cope with misfolded proteins, but when this
mechanism is overwhelmed, the cell faces enormous stress. When unfolded proteins
accumulate in the ER, the cell activates the Unfolded Protein Response (UPR), which
leads to co-ordinated upregulation of the ER chaperones and enzymes and ultimately to
ER stress (Sitia et al. 2003; Zhang et al. 2006). When the degradative capacity of the cell
is also exceeded, the synthesis of proteasomal proteins is induced. If the accumulation of
unfolded proteins continues, it eventually triggers apoptosis (Zhang et al. 2006).
Misfolding diseases
There is a wide variety of human diseases characterized by accumulation of insoluble
extra or intracellular deposits of misfolded proteins, for example Alzheimer disease (AD),
Parkinson disease, Huntington disease, Creutzfeldt-Jakob disease and the Marfan
syndrome.
In AD, the misfolded and accumulated b peptide is generated by the same enzyme, g-
secretase, as N3ICD in CADASIL. AD is the most common neurodegenerative disease
causing dementia. The characteristic manifestation of AD is the accumulation of
extracellular amyloid plaques and intracellular neurofibrillary tangles of
hyperphosphorylated tau protein within neurons (Bossy-Wetzel et al. 2004; Haass et al.
2007). Amyloid plaques contain small cleavage products of the b-amyloid precursor
protein (APP), b-amyloid peptides (Ab) organized in parallel b sheets. Ab is generated by
g-secretase which cleaves APP in the middle of the plasma membrane at sites e, z and g.
The g site is variable and can be located after amino acids 38, 40 or 42. This variability
can lead to generation of Ab42 which has a strong propensity to aggregate (Haass et al.
2007). Environmental factors, or mutations in APP or in presenilin-1 can cause changes in
Ab production or clearance and lead to an increased Ab42/40 ratio, which results in
enhanced plaque formation and clinical AD (Winklhofer et al. 2008). In patients, the
severity of the symptoms does not correlate with the number of the Ab plaques but rather
with cerebral concentrations of soluble Ab monomers and oligomers (Haass et al. 2007;
Selkoe 2003). Therefore, it has been suggested that insoluble plaques serve as a reservoir
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for soluble Ab protofibrils which are toxic and cause neurodegeneration (Bossy-Wetzel et
al. 2004; Haass et al. 2007; Selkoe 2003).
Another misfolding disease having similarities with CADASIL is Marfan syndrome.
Marfan syndrome is the most common inherited multisystem disorder of connective
tissue. The most common cardiovascular manifestation of Marfan syndrome is the
dilatation of the ascending aorta, which leads to aortic aneurysms (Ammash et al. 2008).
Marfan syndrome is caused by over 500 different mutations in the FBN-1 gene, which
codes for a large ECM protein, Fibrillin-1 containing 47 EGF repeats (Whiteman et al.
2006b). In the ECM, Fibrillin-1 forms large structural components, microfibrils, which
are involved in elastic fibre homeostasis found in the tissues as in aortic media. Over 40%
of the mutations cause either a substitution or creation of one cysteine residue in the
calcium binding EGF repeats and, thus, cause a misfolding of the protein. Analyses of the
expression of mutated Fibrillin-1 in fibroblasts have revealed a variety of defects in the
synthesis, trafficking, and incorporation of Fibrillin-1 into the ECM. All these
mechanisms are suggested to result in an impairment of microfibril function, either
through a reduction in the amount of Fibrillin-1, inhibition of microfibril assembly, or
production of abnormal microfibrils (Whiteman et al. 2006b). Detailed studies of the
structural effects of the cysteine substitution in the 29th calcium-binding EGF repeat in the
fragment containing calcium-binding EGF repeats 29-31 showed that the mutated EGF
repeat is substantially more susceptible to proteolytic cleavage than the wild type EGF
repeat. In addition, the mutation causes a loss of calcium binding in the affected calcium-
binding EGF repeat (Whiteman et al. 2006b). Mutations in Fibrillin-1 seem to cause
heterogenic structural differences with variable effects on Fibrillin-1 biosynthesis and
trafficking, thus it is suggested that the pathogenesis leading to the Marfan syndrome is
diverse (Whiteman et al. 2006b).
Misfolding in CADASIL
There are over 170 different mutations causing CADASIL (Supplemental Table in Study
IV). Mutations to lead to the accumulation of N3ECD and GOM on the surface of the
VSMC. Practically all the CADASIL mutations lead to an uneven number of cysteine
residues in the mutated EGF repeat. Both calcium-binding and non-calcium-binding EGF
repeats are equally affected. An uneven number of cysteines leads to an abnormal
formation of sulphur bridges and leaves an unpaired and thus active cysteine residue free.
The unpaired cysteine residue may form a disulphide bond with another NOTCH3
receptor or with another cysteine containing proteins (Dichgans et al. 2000) and thereby
lead to protein aggregation. Impaired disulphide bonding might also disrupt the
stabilization of b sheets and alter the 3-dimensional structure of an EGF repeat, affect
calcium binding and make the receptor more susceptible or resistant to proteolytic
degradation (Whiteman et al. 2006b).
However, there are seven point mutations and one deletion that do not contain a cysteine
deletion or substitution yet also cause vascular dementia similar to CADASIL (Okeda, et
al. 2002; Uchino, et al. 2002; Mazzei, et al. 2004; Kim, et al. 2006; Ferreira, et al. 2007a;
Ferreira, et al. 2007b; Mizuno, et al. 2008; Scheid, et al. 2008). In adition, one frameshift
deletion causing a stop codon at amino acid 159 has been reported (Dotti, et al. 2004).
Most of these cases have not been examined for the accumulation of N3ECD or for the
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presence of GOM and therefre, it is unclear, whether these mutations cause classic
CADASIL or some other cerebrovascular disease.
In adition to an altered cysteine number, domain misfolding may be induced by mutations
which replace an amino acid that is important for domain folding. These mutations may
cause steric hindrance and prevent the correct folding of the domain. Two of these point
mutations (p.Thr577Ala and p.Ser978Arg) cause amino acid substitutions where the
charge of the side chain is changed (Ferreira et al. 2007a; Ferreira et al. 2007b). Two
other point mutations (p.Arg75Pro and p.Ala1020Pro) lead to amino acid substitutions of
proline, which is a common amino acid in forming b sheet turns and may disrupt correct
protein folding (Kim et al. 2006; Mizuno et al. 2008; Scheid et al. 2008). GOM has been
detected in the skin biopsy of a patient carrying the p.Arg75Pro mutation and it therefore
seems that at least this mutation can cause CADASIL (Mizuno et al. 2008). One of the
point mutations (p.Val237Met) replaces a conserved valine of a calcium binding site in
the 6th EGF repeat and thereby propably disrupts calcium binding (Uchino et al. 2002;
Whiteman et al. 2006a). The deletion (p.Ala88_Gly91del) falls between the 2nd and 3rd
cysteine in EGF repeat 2 and deletes non-conserved amino acids. It, however, brings the
two cysteines only one residue apart from each other and, by that means, might cause
incorrect disulphide pairing (Mazzei et al. 2004). One of the point mutations does not
seem to have substantial consequences for the domain folding properties. The mutation
(p.Arg213Lys) replaces arginine with a basic side chain with lysine that also has a basic
side chain, which furthermore is close to the same size (Okeda et al. 2002). Deletion of 5
base pairs leads to frameshift of the reading frame causing a nonsense stretch of amino
acids from amino acid 127 to 158 and genertion of a stop codon at amino acid 159 which
leads to premature termination of translation and thus to truncated receptor (Dotti et al.
2004)
2.8.2 Impaired maturation, targeting and “sop-up”
In CADASIL, N3ECD accumulates on VSMCs in arteries (Joutel et al. 2000). The
accumulation of N3ECD on the surface of VSMCs has been considered pivotal in
CADASIL, though the reason for the accumulation has remained unclear. In cell surface
biotinylation assays, it has been demonstrated that the mutated NOTCH3 is correctly
targeted to the cell surface (Haritunians et al. 2002; Low et al. 2006; Joutel et al. 2004;
Peters et al. 2004; Karlstrom et al. 2002). Impaired proteolytic maturation of the receptor
has been suggested as a possible cause of CADASIL. Three studies have reported
impaired or protracted S1 cleavage (Haritunians et al. 2002; Peters et al. 2004; Karlstrom
et al. 2002), whereas the other two studies reported that the mutated NOTCH3 was
processed correctly (Low et al. 2006; Joutel et al. 2004). Two studies have reported
intracellular aggregates, although similar aggregates were also detected in the wild type
NOTCH3 expressing cells (Low et al. 2006; Karlstrom et al.et al. 2002). Artificial
overexpression of a protein in a cell system might cause protein aggregation, improper
processing and targeting. Therefore, there is no convincing evidence for the impairment
of NOTCH3 maturation, and it seems that in CADASIL, the mutated NOTCH3 matures
correctly. The ER quality control should recognize misfolded proteins and direct them for
polyubiquitylation and subsequent proteosomal degradation (Haglund et al. 2003).
However, the mutated NOTCH3 seems to escape this quality control, and it is transported
to the cell surface (Low et al. 2006; Joutel et al. 2004; Peters et al. 2004; Karlstrom et al.
30
2002). Why N3ECD accumulates and why it is not cleared from the plasma membrane
may be related to impaired endocytosis.
O-linked fucosylation is suggested to play a role in CADASIL pathology. The O-
fucosyltransferase glycosylates only properly-folded EGF repeats, and it is suggested that
this enzyme plays a role in the quality control of protein folding. It was proposed that
CADASIL mutations cause a change in the NOTCH3 tertiary structure or aggregation
state, thus impairing the recognition by Fringe, resulting in the impairment of both
elongation of O-linked glycosylation and proteolytic maturation (Arboleda-Velasquez et
al. 2005). Impaired elongation of the O-linked glycosylation could alter the ligand
selectivity of the NOTCH3 protein and thereby, modify the physiological function of the
receptor (Panin et al. 1997) and so contribute to CADASIL pathology.
N3ECD accumulates in almost identical amounts in the arteries of CADASIL patients
regardless of whether the mutation is located at the LRS or not, indicating that DSL
ligand binding is not a prerequisite for N3ECD accumulation (Joutel et al. 2004). After
ligand binding, the wild type N3ECD is cleared from the plasma membrane by
transendocytosis with the ligand to the signal-sending cell and degraded (Nichols et al.
2007a; Parks et al. 2000). It is not known if the mutated N3ECD is transendocytosed or
not. The cell surface expression of the wild type NOTCH3 is regulated by constant
endocytosis (Wilkin et al. 2005; Nichols et al. 2007b; Chastagner et al. 2008). Whether
the mutated NOTCH3 can also be endocytosed is currently unresolved. The importance of
endocytosis for DSL ligand activation has been demonstrated (Wang et al. 2004; Heuss et
al. 2008), but it is not known whether NOTCH requires a similar maturation process to
become an effective receptor. An impairment in the endocytotic recycling/degradation
pathway could lead to accumulation of N3ECD.
Accumulation of the mutated N3ECD has been suggested to cover the cell surface and
therefore to “sop up” the ligands for NOTCH and for other receptors without transmitting
the signal (Spinner 2000). This could lead to disturbances in the cell-cell and cell-
extracellular matrix interactions, including ligand binding, which could seriously impair
signalling that is crucial for cell survival, for example inhibition of apoptosis (Wang et al.
2002). However, in the transgenic (tg) mice expressing human NOTCH3 with mutation
p.Arg90Cys (NOTCH3R90C), the function (RBP-Jk activity) of NOTCH3 was normal in
one and 12-month-old mice with no dominant negative interfering activity despite the
accumulation of mutated N3ECD on the VSMCs (Monet et al. 2007). This suggests that
the mutated NOTCH3 does not have such a dominant negative “sop up” effect. On the
other hand, the accumulation of N3ECD in short-lived mice may not be comparable to
that caused by the decades-long human CADASIL and due to differences between the
species, not all data from animal models may be directly applicable in humans.
2.8.3 Gain or loss of function
Several CADASIL cases are caused by mutations located in the LRS and even then, the
clinical outcome is identical to those with the mutation outside of the LRS. Since
CADASIL VSMCs degenerate and NOTCH3 signalling is shown to inhibit apoptosis and
regulate VSMC growth by the RPB-Jk–dependent pathway, it has been postulated that the
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NOTCH3 signalling is impaired in CADASIL. However, it has been demonstrated by
several studies in virto and in vivo that only specific mutations located in the LRS in EGF
repeats 10-11 (p.Cys428Ser and p.Cys455Arg) exhibit a significant reduction of
transcriptional activity via the RBP-Jk-dependent pathway. All the other mutations tested
so far are shown to have close to normal signalling activity and ligand binding
(Haritunians et al. 2002; Low et al. 2006; Joutel et al. 2004; Peters et al. 2004; Karlstrom
et al. 2002, Monet-Leprêtre et al. 2009). Thus, it seems highly unlikely that a loss of the
canonical NOTCH3 signalling alone would be the cause of CADASIL. However, most of
the signalling studies have been carried out with overexpressing cell systems, which
might cause leakage in the signalling regulation, and were limited to the canonical
NOTCH signalling, the physiological relevance of which is questionable since the
expression of the target genes of this pathway is not affected even in Notch3 deficient
mice (Domenga et al. 2004). On the other hand, physiological levels of wild type human
NOTCH3 and the mutant p.Arg90Cys human NOTCH3 rescued the arterial defects of
Notch3-/- mice to similar degrees and exhibit a normal level of NOTCH3/RBP-Jk activity
in the brain arteries. Just recently, Notch3-/- mice expressing a human transgene NOTCH3
with mutation p.Cys428Ser at LRS was shown to have an abrogated RBP-Jk activity and
the arteries of these mice resambled the arteries of Notch3-/- mice (Monet-Leprêtre et al.
2009). These studies indicate that if the mutation is outside the LRS, the mutated
NOTCH3 is functional and fully capable of rescuing the arteries from NOTCH3 depletion
during postnatal arterial maturation and able to sustain the arterial integrity in up to 12-
month old mice (Monet et al. 2007). On the other hand, mutation at the LRS generates a
non-functional receptor and leads to a phenotype similar to Notch3 deficient mice
(Monet-Leprêtre et al. 2009). In humans, there is no widely acknowlendged difference in
the phenotype of CADASIL patients. Cohort of ten CADASIL patients carrying the
mutation at the LRS were associated with larger volume of white matter hyperintensities
and relatively perserved congitive performances (Monet-Leprêtre et al. 2009). It therefore
seems possible that in human NOTCH3 canonical signalling has compensatory
mechanisms in vivo or that in human NOTCH3 might have some other unidentified
ligand(s) or signalling pathway(s) distinct from the canonical pathway that regulates
VSMC function and survival affected by NOTCH3 mutations (Wang, et al. 2008) or the
mutation might generate a novel toxic function.
Evidence against the increased function of the NOTCH3 receptor is based on the same
experiments as for the loss of function, i.e. cells expressing the mutated NOTCH3 show
normal signalling activity (Haritunians et al. 2002; Low et al. 2006; Joutel et al. 2004;
Peters et al. 2004; Karlstrom et al. 2002). Interestingly, gain of NOTCH3 function was
reported in a patient with cerebral small-vessel-disease lacking GOM deposits and
NOTCH3 accumulation. This mutation is located in the juxtamembranous region of
NOTCH3, which constitutes the heterodimerisation domain (Figure 2). This mutation
destabilises the metal ion bridge leading to a ligand-independent release of N3ECD, thus
to a constitutively active receptor. It seems that gain of function leads to another cerebral
small-vessel-disease considered different from CADASIL (Fouillade et al. 2008).
The other face of protein misfolding is the gain of toxic function. In neurodegenerative
diseases, such as AD, the misfolding and accumulating material is shown to be toxic for
the neuronal tissue and to inhibit neurotransmission (Winklhofer et al. 2008). It has been
suggested that the accumulated mutated N3ECD or GOM could be toxic and trigger the
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degeneration of VSMCs. However, in tg NOTCHR90C mice, the degeneration of VSMCs
appeared before any GOM was detected. On the other hand, this could be similar to the
mechanism in AD, where the toxicity is caused by the soluble dimers and oligomers
rather than the insoluble fibrillary amyloid aggregates (Bossy-Wetzel et al. 2004; Haass et
al. 2007; Selkoe 2003). Therefore, GOM could just serve as a harmless reservoir for still-
soluble components of N3ECD or GOM.
2.8.4 Altered signaling pathways
Failure in anti-apoptotic signaling
Arterial VSMCs degenerate in CADASIL patients. In aged patients, arterial VSMCs can
be degenerated so extensively that only some ghost-like VSMCs are present (Ruchoux et
al. 1997). NOTCH3 has been associated with the inhibition of apoptosis and promotion of
VSMC survival by the RBP-Jk-independent and dependent mechanisms (Wang et al.
2002; Sweeney et al. 2004). In addition, both serum withdrawal and Fas ligand-induced
cell death was reduced by activation of a NOTCH3 target gene, HRT1, expression, thus
inducing an anti-apoptotic phenotype in VSMCs. HRT1 signalling promotes VSMC
survival by inducing the expression of Akt, which is a key modulator of common
apoptotic pathways (Wang et al. 2003). Therefore, it is possible that NOTCH3 promotes
survival by several different mechanisms, which may be parallel and cell specific. It has
been suggested that in CADASIL, the mutations in NOTCH3 could impair this anti-
apoptotic function and lead to VSMC degeneration.
Impaired vasoregulation
It has been suggested that NOTCH3 is involved in the regulation of actin cytoskeleton
and vascular mechanotransduction, and could act as a sensor or a signal transmitter that
enables VSMC to respond to mechanical stretching of the vessel wall (Domenga et al.
2004). Microfibrillar proteins located in the ECM of blood vessels, MAGP-1 and 2, are
able to bind to NOTCH1, dissociate the ECD and activate the NOTCH1 canonical
signalling (Miyamoto et al. 2006), thereby serving as possible mechanotransduction
ligands for NOTCH receptors. Furthermore, there is evidence that activated NOTCH1 and
NOTCH4 ICD can activate integrins and enhance their binding avidity to ECM (Leong et
al. 2002; Karsan 2008). However, there is no corresponding data for NOTCH3.
Vasoregulation problems are well established in CADASIL. CBF, especially in cerebral
white matter, is already reduced in the asymptomatic phase (Tuominen et al. 2004). The
diameter of retinal arterioles, which correspond to the cortical arteries in the brain, are
smaller than in the age-matched controls, and they appear similarly contracted to those
found in hypertensive patients (Roine et al. 2006). The endothelium-dependent
vasodilation is impaired in peripheral resistance arteries (Stenborg et al. 2007), and the
isolated arteries have enhanced maximal constriction in response to angiotensin II, which
is a major vasoconstrictor agent (Hussain et al. 2004). Arteries in the tg NOTCH3R90C
mice are demonstrated to have increased resistance and decreased relaxation in response
to acetazolamide and hypercapnia (Lacombe et al. 2005). In addition, these mice show an
impairment of vascular mechanotransduction already before VSMC degeneration, GOM
deposits, and N3ECD accumulation occur. Endothelium-dependent, flow-induced
vasodilation is significantly decreased and pressure-induced myogenic tone increased in
the arteries in these mice compared to the wild type arteries (Dubroca et al. 2005).
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It is intriguing that CADASIL patients and the tg NOTCH3R90C mice exhibit opposing
vasoregulatory impairments compared to Notch3-/- mice. These data indicate that the
NOTCH3 function is increased in CADASIL. However, it has been demonstrated, both in
vitro and in vivo, that mutations outside the LRS in NOTCH3 do not effect the canonical
NOTCH3 signalling (Haritunians et al. 2002; Low et al. 2006; Joutel et al. 2004; Peters et
al. 2004; Karlstrom et al. 2002; Monet et al. 2007). On the other hand, in Notch3-/- mice,
there is no difference in the expression of canonical NOTCH downstream target genes
compared to the wild type mice (Domenga et al. 2004). Thus, the results of
vasoregulation studies also suggest that CADASIL-type mutations in NOTCH3 do not
alter the function of the receptor by decreasing or increasing the canonical signal activity,
but rather by affecting a yet-unidentified pathway or gaining of a new toxic function.
Fibrotic pathway
In CADASIL patients, the walls of the affected arteries in cerebral white matter become
markedly thickened, mainly due to accumulation of type I collagen, resulting in stenosis,
which obviously reduces blood flow and causes ischemic infarctions (Miao et al. 2004,
Kalimo et al. 2008). NICD is an inhibitory factor in the TGF-b signalling pathway (Sun et
al. 2005), which has an important role in physiological functions and pathological
processes, expecially in the development of fibrosis (Dabek et al. 2006). The TGF-b
superfamily consists of several proteins, but TGF-b1 is the most abundantly expressed in
the vasculature. VSMC is one of the most important cell types able to produce and
respond to TGF-b. TGF-b is secreted as an inactive dimer associated with the latency-
associated protein and the latent TGF-b binding protein. TGF-b is activated by
extracellular enzymes, such as plasmin, and matrix metalloproteases. Active TGF-b binds
two members of the kinase receptors, R1 and R2. In healthy VSMCs, the R1 receptor
predominates and activates production of contractile proteins. In a diseased vessel, the
predominant receptor is type R2, which induces collagen production and thereby
promotes fibrotic effects in the vasculature (Dabek et al. 2006). Altered NOTCH3
signalling could lead to change in the the cross-talk between TGF-b intracellular
signalling proteins, smads, and the NOTCH3 signalling pathway. This could switch the
TGF-b activity towards production of ECM proteins and thus to fibrosis
2.9 Diagnosis and therapy
CADASIL is suspected in patients with typical clinical features (see Clinical
characteristics), suggestive family history and white matter alterations in T2wMRI
(O'Sullivan et al. 2001). Definite verification of the diagnosis can be achieved by
identifying a pathogenic mutation in the NOTCH3 gene. At least 170 different mutations
in 20 different exons and 2 introns have been reported to cause CADASIL (Supplemental
Table in Study IV). Comprehensive analysis of all these exons is time-consuming and
costly. In families with a known mutation, the test is directed towards that mutation, for
example with a restriction enzyme analysis. In populations with known founder or major
mutations, such as the p.Arg133Cys mutation in Finland, the analyses are first focussed
on those mutations. Most diagnostic laboratories screen only those exons of the NOTCH3
gene that, according to the previous reports, harbour the majority of the mutations, i.e.
exons 3, 4, 5 and 8. If the mutation is not found in these exons, the screening is continued
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to exons 2, 6, 11 and 18 (Joutel et al. 1997; Dotti et al. 2005; Escary et al. 2000; Opherk
et al. 2004).
EM detection of GOM can be used in diagnostics, since it is relatively easy to perform
and also CADASIL-specific since GOM has not been described in any other disease
entity. Most commonly, the biopsy is taken from the skin, but other neuropathological
biopsies, for example biopsies from the muscle or peripheral nerves can also be used
(Ruchoux et al. 1995; Ruchoux et al. 1994). However, reports on the sensitivity of
detecting GOM in skin biopsies of patients with genetically verified CADASIL have been
very variable, ranging from 100% to 44.4% or even lower (Markus et al. 2002; Ebke et al.
1997; Mayer et al. 1999; Razvi et al. 2003). Another morphological diagnostic method is
the immunohistochemical demonstration of accumulated N3ECD (Joutel et al. 2001). An
unfortunate caveat of this technique is false positive immunoreactivity in other diseases or
even in healthy controls, which reduces its specificity (Lesnik Oberstein et al. 2003). In
addition, some false negative results have been reported in samples with a mutation in
exon 11. These mutations are not located at the antibody epitope site but highlight the
important fact that misfolding of the mutated receptor can impair antibody recognition
(Joutel et al. 2001; Lesnik Oberstein et al. 2003). In addition, at the early stages of the
disease when only a small amount of N3ECD has accumulated, the immunodetection can
be very difficult or even impossible.
Since the pathogenesis is still unknown, only symptomatic treatment is available for
CADASIL patients. Local thromboses are thought to give rise to vascular pathology and
therefore anticoagulants and antiaggregants have been used to prevent artery occlusion
without clearly beneficial effects for the patient. Moreover, in a few patients,
anticoagulant therapy has been associated with fatal parenchymal brain haemorrhages
(Kalimo et al. 2008). Cholinergic deficits have been detected in CADASIL patients
(Manganelli et al. 2008; Keverne et al. 2007) and a cholinesterase inhibitor treatment has
been shown to improve executive functions. However, the clinical relevance of this
treatment is yet not known (Dichgans et al. 2008). CADASIL patients should avoid
ergotamines and triptans as a medication for migrainous headache since they can cause
vasospasm and endanger the already reduced CBF. In addition, medication causing
reduced CBF, such as hypotensive drugs, tricyclic antidepressants and neuroleptics,
should be used with caution (Kalimo et al. 2008).
2.9.1 New therapeutic possibilities
In another misfolding disease, AD, two main therapeutical approaches have been applied:
to reduce (1) the generation of Ab by g-secretase inhibitors or (2) the Ab toxicity by anti-
aggregation agents and immunotherapies (Aisen 2008). Inhibiting g-secretase, which is
also the enzyme cleaving NOTCH3, by inhibitors would reduce NOTCH3 activity.
Because NOTCH3 function is required in adult arteries, the complete inhibition of
NOTCH3 would very likely be disadvantageous. Reduction of the suggested toxicity of
the accumulated material in CADASIL could be a new therapeutic target. Immunotherapy
directed against N3ECD and/or yet unidentified components of GOM could reduce the
VSMC degeneration if these components are proven toxic for the cells. The inhibition of
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vascular fibrosis with anti-fibrotic therapy could reduce narrowing of the arterial lumen
and circulatory disturbances in the brain (Ruiz-Ortega et al. 2007).
The discovery of small interfering RNAs (siRNA) as downregulators of gene expression
has opened new therapeutic possibilities, providing powerful tools to reduce the
expression of single genes. RNA interference is initiated when a double stranded RNA is
processed by a dicer enzyme into small 21 to 23-nucleotide-long RNA molecules. siRNA
couples with the protein complex called the RNA-induced silencing complex (RISC) and
mediates sequence-specific cleavage and destruction of the complementary messenger
RNA (mRNA), which leads to reduced translation of the siRNA target genes (Rodriguez-
Lebron et al. 2006). Human diseases, where a point mutation causes dominant, toxic
effects, could be treated by silencing specifically the mutated allele and leaving the
normal allele undisturbed. Allele-specific siRNAs have already been designed for several
diseases, including the familial forms of Alzheimer disease, Parkinson disease, and
amyotrophic lateral sclerosis (Koutsilieri et al. 2007). The challenge of silencing only the
mutated allele is the design of an siRNA which will discriminate between the normal and
mutated allele. The major contributing factor is the type of base-pair mismatch between
target RNA and siRNA; the best discrimination seems to be with purine-purine mismatch
and poorest with pyrimidine-pyrimidine mismatch (Schwarz et al. 2006). If CADASIL
pathology is caused by a gain of toxic function, the suppression of the mutated allele
could rescue VSMCs from degeneration and prevent the deleterious vascular pathology.
The wide variety of mutations may not make CADASIL the most attractive target for
allele-specific therapy, but with the increasing development of personalized medicine, it
may be more realistic
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3 VASCULATURE
Development of the vasculature system is crucial for ontogenesis, and it is one of the
earliest events in organogenesis. Vasculogenesis is de novo formation of the vasculature
during early embryogenesis, in which the angiogenic progenitor cells migrate to the sites
of vascularization, differentiate into endothelial cells and form the primary capillary
plexus. Angiogenesis is the expansion of the pre-existing vessel network through
combination of sprouting, proliferation and remodelling processes. Extensive angiogenic
remodelling converts the primary capillary plexus into arteries, veins and capillary beds
(Semenza 2007; Roca 2007). Blood vessels form an extensive hierarchial network which
serves as a conduit system for blood circulation, which is needed for transporting oxygen
and nutrients to the tissues and removing cellular metabolites from them.
3.1 Structure of blood vessels
The wall of a blood vessel consists of three layers (Figure 4). The luminal side of blood
vessels, tunica intima, is composed of an inner layer of endothelial cells, which forms a
non-coagulant surface for the blood and regulates the influx of molecules from the blood
stream. The endothelial cell layer is supported by the basement membrane surrounded by
a subendothelial space which also contains internal elastic lamina, a membrane formed
by elastic fibres. The middle layer of blood vessels, tunica media, is composed of a
circumferential layer of SMC and elastic fibres containing collagens, laminins and
proteoglycans. The SMC layer can be very thick in the arteries compared to the veins.
Tunica media reaches out until the outermost layer of the blood vessel, tunica adventitia.
Tunica adventitia is a layer of connective tissue formed by collagen and elastic fibres and
some pericytes. This layer connects the blood vessel to its surroundings. In arteries, a
membrane called external elastic lamina separates tunica media and tunica adventitia.
Cerebral arteries differ from systemic arteries by having a blood-brain-barrier (BBB) that
is formed of non-fenestrated endothelial cells joined by tight junctions between the cells.
The BBB restricts the passage of various molecules from the blood circulation to the
brain parenchyma. The cerebral arteries also lack the external elastic lamina membrane
(Lee 1995).
Large arteries (diameter > 1 cm), like the aorta and main arteries branching from it,
transport a high-pressure blood flow from the heart to the body. Large arteries have a
fairly thick tunica intima and flattened endothelial cells. Middle-sized arteries (1-10 mm)
supply blood to the tissues and organs. They have a thinner tunica intima than the large
arteries. Small resistance arteries (20-100 µm) have a thin tunica adventitia, 2-5 layers of
SMCs and they regulate the blood flow to the capillary network. Capillaries (5-10 µm)
are responsible for effective gas and metabolite exchange in the tissue and they lack
tunica media i.e. SMC layer. They are formed of the endothelial layer, basal lamina and
discontinuous pericyte cell layer.
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3.2 Vascular growth factors: PDGF
Angiogenesis is tightly regulated by signalling pathways directing the proliferation,
sprouting and intercellular signalling of vascular cells. A large group of proteins
regulating vasculogenesis and vascular differentiation include vascular growth factors and
their receptors, among which PDGFs and their receptors comprise an important family of
vascular modulators. There are four different PDGF ligands (A-D) that bind to two
different PDGF receptor tyrosine kinases (PDGFR-a and b). All PDGFs are disulphide-
linked homodimers. In vivo, there is functional evidence only for interactions between
PDGF-AA and -CC with PDGFR-a, and PDGF-BB with PDGFR-b (Andrae et al. 2008).
The expression of PDGFs and PDGFRs is dynamic and spatio-temporally regulated.
PDGF-B is mainly expressed in endothelial cells, megakaryocytes and neurons, and
PDGFR-b is mainly expressed in mesenchyma, pericytes and VSMCs. PDGF-B/PDGFRb
signalling has been shown to be important for vascular development and maintenance
through its role in pericyte and SMC recruitment. During angiogenesis, the sprouting
endothelium expresses PDGF-B, which acts as a short-range paracrine factor recruiting
pericytes and VSMCs. Pdgf-b and Pdgfr-b knockout mice die at late gestation from wide-
spread microvascular hemorrhages and microaneurysms which are caused by mural cell
deficiency (Andrae et al. 2008; Betsholtz 2004). Activation of PDGFR-b leads to
intracellular auto-phosphorylation of this receptor and induction of several intracellular
signalling cascades, including the mitogen-activated protein kinase (MAPK),
Figure 4. Structure of a small artery.
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phosphoinisitol-3 kinase (PI3K) and phospholipase C (PLC) pathways. Activation of the
MAPK pathway leads to the stimulation of cell growth, differentiation and migration. The
PI3K pathway activates several kinases and Rho family GTPases, induces actin
reorganization, directs cell movements, stimulates cell growth and inhibits apoptosis.
Induction of the PLC pathway leads to mobilization of intracellular Ca2+ ions and
activation of protein kinase C (PKC), which subsequently leads to stimulation of cell
growth and motility (Andrae et al. 2008).
3.3 Vascular smooth muscle cells
Smooth muscle differs from skeletal and cardiac muscle by the absence of the striated
banding pattern of sarcomeres, which are the organised structures of thin and thick
filaments. In a smooth muscle cell, the organizational sites for thin and thick filament
interaction are dense bodies, which are similar to the Z lines of the striated muscle
sarcomeres. Like the cardiac muscle, control of the smooth muscle is involuntary, and the
effect of the contraction is 3-dimensional. The specific feature of the smooth muscle is its
slow contraction. SMCs are found mainly in the gastrointestinal tract, uterus, respiratory
tract and blood vessels. VSMCs are highly specialized cells whose main function is
contraction and the regulation of vascular tone and vessel lumen diameter and thereby
blood flow. In a mature blood vessel, VSMCs possess a contractile phenotype and have a
relatively slow proliferation and synthetic activity. They express a unique set of proteins
involved in contraction, ion transport and signalling. Contraction proteins, such as a-
SMA, SMMHC and calponin, are SMC differentiation markers (Rzucidlo 2007). Even in
a mature vessel, VSMCs are not terminally differentiated and can change their phenotype
to synthetic according to the demands of the local environment, and thus have substantial
plasticity. The synthetic phenotype VSMCs have a higher proliferation rate, migration,
and synthesis of ECM components, and at the same time, they show decreased expression
of SMC-specific differentiation markers. This dedifferentiated synthetic phenotype plays
a major role in wound healing and in the pathogenesis of aterosclerosis, intimal
hyperplasia, hypertension and asthma (Rzucidlo et al. 2007).
VSMCs regulate vascular tone and thereby blood pressure by constricting or dilating the
vascular diameter. Hemodynamic forces generated by blood flow play an important role
in the physiological control of vascular tone and remodelling. The pulsative nature of the
blood flow and pressure creates two principal mechanical forces acting directly on the
cells within the blood vessel wall. Fluid shear stress, which acts parallel to the direction of
blood flow and vessel surface, is principally directed towards the endothelium, and cyclic
mechanical stretch, which is perpendicular to the direction of blood flow, acts mainly on
the VSMCs of the tunica media (Williams 1998). VSMCs convert the cyclic mechanical
stretch into biochemical signals that regulate proliferation, apoptosis and migration of the
vascular cells and synthesis, degradation and reorganization of the ECM (Morrow et al.
2005a; Morrow et al. 2005b; Haga et al. 2007). Therefore, an increase in the arterial
pressure causing strain on VSMCs can lead to a cascade of events which modify the
arterial wall structure, by inducing VSMCs’ hyperplasia and hypertrophy and increasing
deposition of ECM proteins, including collagens and elastin. This may cause an increase
in the vessel wall thickness and decrease the arterial luminal diameter, which becomes
apparent as an increased sclerotic index. Finally, if these events occur in cerebral vessels,
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they may predispose an ischemic brain infarct and a clinical stroke (Haga et al. 2007;
Tang et al. 2008).
3.4 Vascular smooth muscle cell contraction
The cytoskeleton of VSMCs is composed of thin filaments containing actin, thick
filaments containing myosin and less abundant intermediate filaments composed mainly
of vimentin and desmin. The actin filaments are arranged in hexagonal arrays that form
cable-like bundles and the spaces between the actin filament bundles are occupied by
myosin filaments. The ratio of actin to myosin filaments varies among smooth muscle
tissues of different organs and it is approximately 15:1 in VSMCs (Gunst et al. 2000).
These filaments are interconnected by binding proteins which further link the
cytoskeleton with other functional structures in the cell. The cytoskeleton is needed for
maintaining the cellular structure and adhesion, to generate cellular movement and cell
division and to conduct contraction. Contraction can be initiated by an agonist or
mechanical activation of integrins, receptor tyrosine kinases, G-protein receptors, ion
channels or caveolin structures (Lehoux et al. 2006), which all lead to the activation of
parallel cascades inducing actin polymerization and actomyosin cross-bridge cycling
resulting in crawling of the myosin filament along the actin filament, which is the actual
contraction that generates tension (Gunst et al. 2008; Hilgers et al. 2005). These two
cascades are independent and separately regulated, and they are both required for
contraction (Gunst et al. 2008).
MLC phosphorylation can be induced by a contractile agonist or by a mechanical
stimulus. Angiotensin II is one of the important agonists regulating the vascular tone.
Angiotensin II binds to the G-protein receptor, which activates PLC that catalyses the
formation of second messengers, inositol 1,4,5-triphosphate (IP3) and diacylglycerol
(DAG). IP3 induces the release of Ca2+ from the ER to the cytosol. Increased cytosolic
Ca2+ concentration activates calmodulin, which further activates MLC kinase that leads to
increased MLC phosphorylation. Mechanical stretch can also induce the increase of the
cytosolic Ca2+ concentration by opening plasma membrane L-type Ca2+-channels, and by
production of DAG which is released by stretch-induced PLC activation. DAG activates
PKC, which has several target proteins, such as Rho kinase that promotes MLC
phosphorylation (Hilgers,et al. 2005). Phosphorylation of MLC enables the interaction
between myosin and actin. The myosin ATPase activity releases energy from adenosine
triphosphate (ATP) and results in the cycling of the myosin cross-bridges with actin and
movement of the thick filament along the thin filament, thus leading to cell contraction
(Hilgers et al. 2005).
It was long believed that actin filaments are rather rigid structures which are not actively
modified during a contractile stimulus. An increasing number of studies support the
dynamic role of the actin cytoskeleton in SMC mechanotransduction and tension
development. A contractile stimulus activates the assembly of adhesion complexes at the
cell surface which directs the actin polymerization and branching at the cell cortex.
Further inwards from the membrane, the filaments are long and unbranched (Pollard et al.
2003). The actin filament mesh formed at the cell cortex may serve as a strengthening
network to transmit further the force generated by the contractile apparatus. The dynamic
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nature of the cortical actin mesh may also enable the VSMSs to adapt to the needs of the
changing environment (Gunst et al. 2008).
3.4.1 Actin filament turnover
The actin cytoskeleton in SMCs is a dynamic structure, and the actin polymerization-
depolymerization participates in the contraction-relaxation cycle and in force
development. Actin is the most abundant protein in cells and exists in a globular form (G-
actin), which is soluble, and in a filamentous form (F-actin), which is a polymeric double-
stranded helical structure of actin monomers (Figure 5). Monomers from the soluble pool
are in constant exchange with the monomers of F-actin, and the F-actin/G-actin ratio
increases in response to contractile stimulus (Gunst et al. 2008). F-actin has a molecular
polarity, and the actin monomers are assembled and disassembled by a cycle called
treadmilling. The growing end, where ATP-bound actin monomers associate to the
filament, is a barbed end. The actin-bound ATP is hydrolyzed to adenosine
monophosphate (ADP) and the ADP-actin dissociates at the other end of the filament, at
the pointed end. ATP hydrolysis is essential to the continuous treadmilling. Treadmilling
is very slow without the regulating and promoting proteins which are necessary to obtain
a physiological function (Pollard et al. 2003).
The polymerization of actin is regulated by proteins which control the availability of the
G-actin pool for incorporation into the actin filaments, and proteins controlling the
availability of the barbed ends of the growing filament (Gunst et al. 2008). An important
actin-associated protein is profilin, which regulates actin dynamics and organization and
interacts with central regulatory proteins, such as the Wiscot-Aldrich Syndrome proteins
(WASp) and Rho family GTPases (Watanabe et al. 1999; Higgs et al. 2000). Profilin
binds to G-actin and transports the monomers to the barbed ends of the filaments. It
catalyzes the exchange of actin-bound ADP for ATP, thus regulating the availability of
the ATP-G-actin pool for incorporation into the F-actin (Tang et al. 2008; Pollard et al.
2003; Gutsche-Perelroizen et al. 1999). Membrane-released phosphoinositides and Rho
family GTPases activate WASp which is an important activator of the Actin-related
proteins 2 and 3 (Arp2/3) complex (Pollard et al. 2003; Takenawa et al. 2007). The
Arp2/3 complex binds to actin filaments and initiates actin nucleation and growth of new
filaments as a branch to the existing one at a 70-degree angle. It also caps the pointed
ends of F-actin, thus inhibiting depolymerization (Tang et al. 2008; Gunst et al. 2008;
Pollard, et al. 2003). Cofilin causes depolymerization at the pointed end of filaments.
Cofilin promotes phosphate dissociation from ATP-actin, severs F-actin and promotes
dissociation of ADP-actin from the end of the filaments. Rho family GTPases induce
cofilin phosphorylation by LIM kinases, which slows down the turnover of the filaments
(Pollard 2003).
3.4.2 Adhesion complexes
The actin filaments are anchored to the plasma membrane via adhesion complex proteins
which are associated with the cytoplasmic tails of integrins (Figure 5). The integrins link
the cytoskeleton to the ECM (Gunst et al. 2008). In tissues, the membrane-associated
adhesion complexes are called dense plaques, and they are structurally similar to focal
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adhesion sites in cultured cells (Tang et al. 2008; Gunst et al. 2000). The adhesion
complexes are composed of dozens of proteins involved in structures that crosslink actin
and other cellular filaments to integrins, and proteins that are involved in the signalling
and regulation of actin reorganization. The adhesion complexes are dynamic structures
with proteins continuously associating and dissociating according to the received signals.
The adhesion complexes are molecularly heterogenous, taking the form of early-state
focal complexes, classical elongated focal adhesions and fibrillar adhesions (Zaidel-Bar et
al. 2004). The adhesion complexes are involved in a bidirectional crosstalk from ECM to
the cytoskeleton and vice versa. The signalling is mediated by allosteric changes of
integrins that transmit the signals from one end of the molecule to the other (Wiesner et
al. 2005).
Integrins are adhesion proteins, heterodimeric class I transmembrane receptors, composed
of a and b subunits providing a mechanically strong connection between the cell and the
ECM. Integrins cluster into the adhesion complexes which serve as attachment points to
actin stress fibres. The extracellular domains of integrins bind to ECM components, such
as laminin, collagens, vimentin and fibronectin, and the intracellular domains bind to
effector proteins directly or indirectly associated to the actin cytoskeleton (Wiesner et al.
2005). In outside-in signalling, the integrin activation triggers several intracellular
messenger systems, including tyrosine and serine/threonine kinases, phosphatases, Rho
family GTPases and binding proteins and MAPK, leading to actin polymerization and
reorganization. Inside-out signalling can lead to integrin activation and enhanced integrin
avidity to the ECM components (Romer et al. 2006).
The adhesion complexes contain signalling and structural proteins cross-linking integrins
with the cellular filaments. Focal complexes form under the leading edge of the cell and
contain talin and paxillin. Mature focal complexes also contain vinculin, focal adhesion
kinase (FAK) and a-actinin (Figure 5) (Zaidel-Bar et al. 2004, Wiesner et al. 2005).
Actomyosin-driven contraction applies force at the cell-matrix adhesions and induces
transition of focal complexes into focal adhesions. Transition is initated by focal complex
growth and accompanied by recruitment of the additional proteins zyxin and tensin. The
development of the elongated focal adhesions is dependent on two Rho target proteins,
Rho kinase and mDia. Mechanical force appears to be also involved in focal adhesion
turnover and formation of fibrillar adhesions. Fibrillar adhesions contain high levels of
tensin and are distributed in more central areas under the cells (Zaidel-Bar et al. 2004).
Vinculin is a key regulator of the adhesions complexes; it has numerous binding partners
and it is also the major link of the focal adhesions to the actin cytoskeleton. An interaction
of activated vinculin with talin has a direct effect on integrins, clustering them at the sites
of the cell-ECM adhesions, possibly by maintaining integrins in an activated state and
leading to focal adhesion enlargement (Humphries et al. 2007). FAK is a non-receptor
tyrosine kinase activated in response to integrin clustering. When FAK is activated it is
auto-phosphorylated on a tyrosine, which creates a binding site for Src family kinases
(Haga et al. 2007; Tang et al. 2008; Wiesner et al. 2005; Romer et al. 2006). The
activation of FAK and c-Src leads to phosphorylation cascades and the activation of
intracellular signalling proteins. FAK interacts with regulators and effectors of the Rho
family GTPases and an adapter protein, paxillin, modulating its interactions with integrin
(Romer et al. 2006).
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3.4.3 Rho GTPases
Several signalling pathways regulate the actin polymerization and organization, among
which the Rho family GTPases are important regulators. The Rho GTPase family
includes 22 proteins in eight different subfamilies. The classic Rho GTPases include the
Rho, Rac and Cdc42 subfamilies,  of which RhoA, Rac1 and Cdc42 are the most studied
(Heasman et al. 2008). The classic Rho GTPases cycle between an inactive guanosine
diphosphate (GDP)-bound form and an active guanosine triphosphate (GTP)-bound form.
The activity of Rho GTPases is regulated by guanine nucleotide exchange factors (Rho-
GEF) that catalyse the change of Rho-bound GDP to GTP, GTPase activating proteins
(Rho-GAP), and guanine nucleotide dissociation inhibitors (Rho-GDI) that stabilize the
inactive GDP-bound form. Rho family GTPases are involved in cell motility, migration
and contraction. Cdc42 regulates filopodium formation, Rac is involved in lamellipodium
extension and Rho induces stress fibre and focal adhesion formation (Ridley et al. 1992).
Several signalling pathways, including agonists induced, such as angiotensin II, and
mechanical stimulus induced, such as integrin activation, can activate Rho GTPases
(Figure 5). RhoA activity is well established in actin polymerization and SMC
contraction. RhoA activates several signalling proteins, such as Rho kinase, which further
activates LIM and MLC kinases. LIM kinase regulates actin polymerization by
inactivating an actin-binding protein, cofilin, thus stabilizing actin filaments (Maekawa et
al. 1999; Matsui et al. 1996).
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Figure 5. A simplified view of focal adhesions and actin filament turnover. The actin filaments are
anchored to the plasma membrane via adhesion complex proteins, such as integrins, vinculin and talin.
Integrins link the cytoskeleton to the ECM and transmit the bidirectional crosstalk from the ECM to the
cytoskeleton and vice versa. Contraction can be initiated by a mechanical activation of integrins or
agonist stimulation of G-protein receptors, both of which lead to the activation of cascades inducing
actin polymerization. Activation of integrins initiate adhesion complex enlargement, leading to actin
polymerization. Both stimuli activate RhoGTPases, which activate Rho kinases and WASp, and affect
adhesion complexes via FAK. WASp is an important activator of the Arp2/3 complex, which binds to
actin filaments and initiates actin nucleation and the growth of new filaments as a branch to the existing
one at a 70-degree angle. Profilin binds to G-actin, catalyzes the exchange of ADP for ATP, and ATP-
G-actin bound to profilin is ready to be incorporated into the barbed end of the growing actin filament.
Cofilin promotes phosphate dissociation from the ATP-actin, severs ADP-actin filaments and enhances
dissociation of the ADP-actin from the pointed end of the filament. Rho kinases induce
phosphorylatation of cofilin by LIM kinases, which slow down the turnover of the filaments.
.
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AIMS OF THE STUDY
The aims of this study were to identify phenotypic differences of VSMCs derived from
CADASIL patients and healthy controls, and to address the reliability of the electron
microscopic detection of GOM in the skin biopsies of CADASIL patients.
The specific aims were:
I To establish VSMC cultures from the umbilical cords of CADASIL patients
and healthy controls and to analyze proteomic differences between these
VSMC lines.
II To establish VSMC cultures from the placenta, systemic arteries and cerebral
arteries of CADASIL patients and healthy controls and to analyse the
expression differences of NOTCH3 and to examine structural differences in
the actin cytoskeleton between these VSMC lines.
III To identify novel target genes for NOTCH and to analyse the expression of a
discovered target gene, PDGFR-b, in response to NOTCH activation in the
cultured VSMCs of CADASIL patients.
IV To clarify the congruence between NOTCH3 mutations and the presence of
GOM detected by electron microscopy with a view to establishing a strategy
for CADASIL diagnostics.
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MATERIALS AND METHODS
The methods used in this study are summarized below. The materials and methods are
described in detail in the original publications as indicated by their assigned Roman
numerals.
Materials/Methods Used in study
Generation of cell lines
· Isolation of VSMCs from arteries of CADASIL patients and healthy
controls
I-III
Molecular genetics
· Verification of the VSMC genotype
· Verification of the patients genotype
I,II
IV
Two-dimensional gel electrophoresis and image analysis
· Separation of proteins by two-dimensional gel electrophoresis
· Scanning and analysis of gels with image analysis software.
I
In-gel digestion and MALDI-TOF analysis
· Digestion of proteins using significant expression differences between
CADASIL and control VSMCs
· Analysis of digested proteins with MALDI-TOF
I
Collagen gel contraction assay
· Analyses of the spontaneous contraction of VSMCs I
Western blot
· Analyses of the expression levels of selected proteins detected with
specific antibodies
I-III
Immunocytochemistry
· Identification of cell types
· Localization of specific proteins and analyses of subcellular structures by
selected antibodies
I-III
Adenoviruses
· Transfection of cells with N1ICD, N3ICD and eGFP III
Activation of NOTCH signalling
· In CADASIL and control VSMCs with immobilized JAGGED-1
· In co-cultures of NOTCH1 and JAGGED-1 expressing cells. Inhibition of
the g-secretase activity by DAPT and of the protein synthesis by
cycloheximide
III
RNA isolation and quantitative RT-PCR
· Isolation of RNA from ligand activated VSMCs
· Quantification of the PDGFR-b RNA
III
Chromatin immunoprecipitation
· Detection of N1ICD binding to the PDGFR-b promoter CSL-binding site III
Cell migration analysis
· Analyses of the effects of N1ICD and N3ICD on the cell migration
towards PDGF-BB
III
Histology, X-Gal staining and Immunohistochemistry
· Morphological and co-expression analyses of Notch3LacZ/LacZ and
Notch3+/LacZ mice, b-gal, endothelial marker PECAM, a-SMA and
PDGFR-b
III
Statistical analyses I-III
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Subjects
· 131 CADASIL patients from Finland (38), Sweden (13) and France (80)
and 26 controls
IV
Transmission electron microscopy
· Detection of GOM in skin biopsies from CADASIL patients IV
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RESULTS
BRIEF SUMMARY OF THE MAIN RESULTS
Study I
A proteome analysis of cultured VSMCs derived from an umbilical cord of a CADASIL
patient carrying the NOTCH3 mutation p.Arg133Cys revealed 11 differentially expressed
proteins when compared to control VSMCs. The proteins were involved in protein
degradation and folding, cellular stress and VSMC contraction. In collagen contraction
assays, CADASIL VSMCs had an impaired spontaneous contraction ability when
compared to control VSMCs.
Study II
a-SMA and phalloidin staining of cultured CADASIL patient VSMCs revealed altered
actin filaments. The actin filaments in CADASIL VSMCs were short; they did not span
the cell but formed bundles and nodes. Vinculin immunostaining of CADASIL VSMCs
showed an increased number of adhesion complexes which were approximately half of
the size as compared to control VSMCs. Analysis of localisation of adhesion complex
proteins suggested a switch in the balance towards fibrillar adhesions. The expression
level of NOTCH3 was higher in VSMCs derived from adults’ systemic and cerebral
arteries when compared to VSMCs derived from placenta or umbilical cord. Alterations
in actin filaments correlated with NOTCH3 expression level.
Study III
In this study, PDGFR-b was identified as a novel immediate NOTCH target gene.
PDGFR-b expression was upregulated by JAGGED-1 activation or by activated forms of
the NOTCH receptor. NOTCH activation induced an increase in the PDGFR-b expression
and led to an augmented intracellular response to PDGF-BB stimulation. In newborn
Notch3-/- mice, VSMCs had a strongly reduced PDGFR-b expression, and later these cells
developed an abnormal morphology. An upregulation of the PDGFR-b mRNA and
protein expression in response to JAGGED-1-induced NOTCH activation was clearly
reduced in VSMCs derived from the umbilical cord of a CADASIL mother’s child
carrying the NOTCH3 p.Arg133Cys mutation.
Study IV
131 Finnish, Swedish and French CADASIL patients, who had been adequately examined
for both the NOTCH3 mutation and presence of GOM, were analysed retrospectively.
GOM was detected in all 131 mutation-positive patients. Mutations included three novel
point mutations (p.Cys67Ser, p.Cys251Tyr and p.Tyr1069Cys) and a novel duplication
(p.Glu434_Leu436dup). All the 131 patients with 33 different pathogenic mutations were
found to be positive for GOM, thus the congruence between the NOTCH3 mutation and
GOM was 100%.
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1 CHARACTERIZATION OF PATIENT CELL LINES
Three VSMC lines were established from umbilical cords and placenta obtained post
partum from three newborn babies whose mothers had CADASIL with the genetically
verified NOTCH3 c.475 C>T (pArg133Cys) mutation (the predominant mutation in
Finland), and from the umbilical cords of three newborn babies to healthy mothers. All
these cell lines were tested for the NOTCH3 c.475C>T mutation. The mutation was
detected in only one VSMC line from the umbilical cord of a CADASIL mother’s baby
and one VSMC line from a CADASIL mother’s placenta. Four other CADASIL cell lines
were generated from arteries of adult patients with the genetically verified NOTCH3
c.475C>T mutation. The arteries were obtained from surgical operations (2) or post
mortem from autopsies (2). The genotype of the VSMCs was further verified in the
cultured cell lines.
The cell lines were identified to be of smooth muscle cells by positive staining with an a-
SMA antibody. CADASIL VSMC lines are characterized by a slower growth rate, a
tighter attachment to the culture surface and a high mortality rate compared to control
VSMCs. In addition, CADASIL cells are larger in size, have an easily detectable nucleus
and reach senescence much earlier than control cells.
VSMCs derived from arteries originating from different tissues exhibit distinct
morphologies. VSMCs derived from the umbilical cord, placenta and adult systemic
vessels are characteristically spindle-shaped SMCs as described in the literature
(Gimbrone et al. 1975). They are elongated, have an easily distinguishable nucleus, orient
themselves in a parallel fashion at confluence and have a tendency to grow in
multilayered aggregates. SMCs from human cerebral subarachnoidal arteries from both
controls and CADASIL patients are more irregular in shape than VSMCs from the
systemic vessels, are less prone to forming multilayered aggregates and exhibit a more
epithelioid SMC-like phenotype (Li et al. 2001). VSMCs derived from the umbilical cord,
systemic and cerebral arteries grow more slowly than VSMCs derived from the placenta
and are larger in size, which applies to both the CADASIL and control cell lines.
2 A PROTEOME ANALYSIS OF PATIENT CADASIL VSMCS
DERIVED FROM AN UMBILICAL CORD
In the whole-cell proteome analysis of protein expression differences in cultured VSMCs
isolated from the umbilical cords of one newborn with CADASIL and five healthy
controls, we detected a total of 626 protein spots. The intensity of 35 protein spots had
statistically significant differences (P<0.05) between CADASIL and the control group.
The quality of the automated spot detection and matching was manually verified. Nine of
the spots, with an additional requirement of a (±) two-fold difference in the spot intensity,
were further selected for a mass spectrometry analysis. In addition, two proteins with a
statistically significant but smaller than (±) two-fold difference in the spot intensity were
selected. Expression levels of eight selected spots were upregulated in CADASIL VSMCs
and three were downregulated.
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Spot
number
Protein name Process
(manual)
Process
(computed)
SwProt
Access
nro
Change
CAD/CTRL
P
7602 Proteasome component
C3
Protein
degradation and
folding
ubiquitin-dependent protein
catabolic process
positive/negative regulation of
ubiquitin-protein ligase activity
during mitotic cell cycle
P25787 1.6 0.0001
3501 Proteasome beta chain Protein
degradation and
folding
ubiquitin-dependent protein
catabolic process
positive/negative regulation of
ubiquitin-protein ligase activity
during mitotic cell cycle
P28070 2.1 0.02
3701 Ubiquitin carboxyl-
terminal esterase L1
Protein
degradation and
folding
axon target recognition
axon transport of mitochondrion
cell proliferation
protein deubiquitination
response to stress
ubiquitin-dependent protein
catabolic process
P09936 0.3 0.0002
2504 Heat shock protein 27 Protein
degradation and
folding
anti-apoptosis
cell motion
response to unfolded protein
P04792 1.7 0.03
1605 Rho protein GDP-
dissociation inhibitor
Cytoskeleton
interaction/SMC
contraction
anti-apoptosis
Rho protein signal transduction
cell motion
negative regulation of cell
adhesion
P52565 3.4 0.000003
8203 Profilin 1 Cytoskeleton
interaction/SMC
contraction
actin cytoskeleton organization P07737 6.3 0.004
1503 Cystein and glycine
rich protein 1
Cytoskeleton
interaction/SMC
contraction
 not defined P21291 3.7 0.05
8501 Superoxide dismutase,
mitochondrial
Free radical
scavenger/cellular
stress
age-dependent response to
reactive oxygen species
negative regulation of apoptosis
release of cytochrome c from
mitochondria
P04179 2.0 0.00004
3606 Glutathione S-
transferase  P1
Free radical
scavenger/cellular
stress
anti-apoptosis
metabolic process
P09211 0.5 0.05
5803 Glutathione S-
transferase omega
Free radical
scavenger/cellular
stress
metabolic process P78417 0.4 0.03
3401 Aspartyl-tRNA
synthetase
other aspartyl-tRNA aminoacylation
protein complex assembly
P14868 5.7 0.00002
Table 1. Identified proteins with significant differences in the expression levels. ‘Spot number’ designates
the spot number in the gel image (Study I). Proteins are associated with different cellular processes described as
Process (manual) and Process (computed). The manual processes are defined by literature searches and the
computed processes by a bioinformatic evalution. A change in the expression level shown as a change in the
average spot intensity of the CADASIL sample is presented as a comparison with the average spot intensity of
the control sample (CADASIL/Control). The significances of the intensity differences were calculated with
One-way ANOVA (p-values).
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Four of the identified proteins are involved in protein degradation and protein folding,
four in the interactions with cytoskeletal proteins and SMC contraction, three related to
cellular stress and one with an unknown function. The expression and identification data
are presented in Table 1.
3 THE COLLAGEN GEL CONTRACTION ASSAY
Due to the fact that the proteomic analysis of the CADASIL VSMCs showed substantial
upregulation of several actin-interacting proteins and those involved in SMC contraction,
we analysed the ability of these cells to contract collagen-rich gels using a CGC assay.
The results demonstrated that the relative collagen gel area is larger in the CADASIL
VSMC culture than in the control VSMC culture. This indicated that the ability of the
CADASIL VSMCs to spontaneously contract collagen gels is markedly diminished
compared to the control VSMCs (p<0.01).
4 THE ALTERED ACTIN CYTOSKELETON IN CADASIL VSMCS
4.1 Actin filaments
Since NOTCH3 has been implicated in smooth muscle cell tone maintenance, and the
proteome analysis showed several alterations in the expression of contraction-related
proteins, we analysed the actin cytoskeleton of VSMCs from CADASIL patients. For this
study, we were able to obtain six additional CADASIL VCMS lines.
The staining of a-SMA revealed disrupted and disorganized a-SMA filaments in the
CADASIL VSMCs compared to control VSMCs. CADASIL VSMCs derived from the
umbilical cord had an almost normal-appearing actin cytoskeleton but CADASIL VSMCs
derived from the placenta were slightly more affected. VSMCs derived from adult tissue
arteries exhibited a reduced amount of F-actin and shorter filaments, some abnormal
nodes and increased branching. The changes were strongest in the VSMCs derived from
CADASIL patients’ cerebral subarachnoidal arteries. In these cells, there were hardly any
F-actin (heterozygous), or the actin filaments were in strong bundles and formed several
nodes (homozygous). In order to test whether the mutation affects the whole actin
cytoskeleton or just the a-SMA organization, we performed phalloidin staining, which
stains all polymerized actin (a, b, and g). The phalloidin staining showed filaments
similar to the a-SMA staining, which suggests that the whole actin filament cytoskeleton
is disrupted in the CADASIL cells in which the filaments are shorter, branched, form
nodes and generally do not span the whole cell.
4.2 Adhesion complexes
To analyse the sites where actin filaments are bound to the plasma membrane, we
analyzed localisation of common adhesion complex proteins. Immunostaining for
vinculin in CADASIL VSMCs showed an increased number of adhesion complexes. The
adhesion complexes were distributed all over the basal surface of the CADASIL VSMCs
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whereas in the control cell lines they were mostly at the edges of the cells. The sizes of
the individual adhesion complexes were smaller in CADASIL VSMCs in comparison
with the elongated adhesion complexes in the control cells. Quantification of the average
area of the adhesion complexes revealed  that in CADASIL VSMCs they were 41 % of
the size of those in the control VSMCs (p<0.02). In addition, Western blot analysis of the
total amount of vinculin showed an increased expression in CADASIL VSMCs when
compared to the corresponding control VSMCs.
Immunostaining for FAK and talin showed co-localization with vinculin, in both
CADASIL and control VSMCs. Immunostaining for phosphotyrosine did not show
difference between control and CADASIL VSMCs. Cortactin immunostaining localize at
the at protrusions and ruffles at the cell edges and the staining was similar in both
CADASIL and in control cell lines. Integrins b5 and av mostly localized into the same
structures with vinculin in both CADASIL and control cells. Integrin b1 colocalized only
partly with vinculin in both CADASIL and control VSMCs. In some elongated adhesion
complexes in control VSMC the co-localization was more evident. In CADASIL VSMCs,
immunostaining for integrin b3 localised more into central areas of the cells as compared
to control cells. Immunostaining for tensin localized into same structures with vinculin
and was stronger in CADASIL as compared to control VSMCs.
4.3 Expression of NOTCH3 and a-SMA
The CADASIL and control VSMCs were immunostained with an antibody, 1E4, which is
directed against N3ECD. N3ECD was clustered in aggregates in CADASIL VSMCs,
whereas control VSMCs had a more uniform staining. The total expression of NOTCH3
and a-SMA were analysed by Western blot. The analysis showed no differences in
NOTCH3 intensity between the CADASIL VSMCs and the corresponding control
VSMCs. The expression of NOTCH3 was significantly higher (p>0.01) in the VSMCs
derived from adult arteries (systemic or cerebral) when compared to VSMCs derived
from the placenta or umbilical cord vessels. The expression was even higher in the
VSMCs derived from the cerebral subarachnoidal arteries, both in the CADASIL and
control VSMCs. In addition, there were no statistically significant differences in the
intensities of full length NOTCH3 or NOTCH3 ECD between the different VSMC-lines.
Despite of the low number of actin filaments in the CADASIL VSMC, the western blot
analysis showed no significant alteration of a-SMA expression in these cells.
5 PDGFR-b IS A NOVEL NOTCH DOWNSTREAM GENE
5.1 Finding of a new target gene
To identify novel NOTCH target downstream genes activated by NICD, (Study III) a
microarray experiment was performed in C2C12 cells infected with adenovirus
expressing N1ICD and control eGFP. The expression of N1ICD led to upregulation of a
number of genes, including PDGFR-b.
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These data were validated by expressing the activated forms of NOTCH1 and NOTCH3
from adenoviral vectors in myogenic cell line C2C12 and detecting the upregulation of
PDGFR-b mRNA levels when compared to the adenoviral control eGFP. The expression
of the canonical NOTCH downstream genes, HEY1 and HES1, from adenoviral vectors in
C2C12 cells did not increase PDGFR-b expression. The NOTCH-PDGFR-b link was also
tested in VSMCs.
To activate the NOTCH signalling via ligand stimulation, the full-length NOTCH1
receptor was expressed in the C2C12 cells, which were co-cultured with the 293T cells
expressing the NOTCH ligand, JAGGED-1. These co-culture experiments, where either
protein synthesis was blocked by cycloheximide or the g-secretase activity was inhibited,
showed that upregulation of the PDGFR-b mRNA expression requires g-secretase activity
and the formation of NICD, but is independent of protein synthesis. The VSMCs, which
expressed increased amounts of PDGFR-b due to the expression of adenoviral N1ICD
and N3ICD were stimulated by PDGF-BB. The PDGF-BB stimulation led to an increased
phosphorylation of PDGFR-b and and its downstream molecule Akt in the Ras/MAPK
pathway when compared to VSMCs expressing only eGFP. In addition, the PDGF-BB
stimulation increased the migration of VSMCs, which, however, was always inhibited by
the expression of N1ICD or N3ICD regardless of the presence of PDGF-BB.
5.2 NOTCH3 upregulates PDGFR-b expression by a distinct
mechanism
The CSL-binding site was found to be required for the N1ICD, N3ICD and NOTCH-
ligand activation-induced upregulation of the PDGFR-b mRNA expression in embryonic
stem cells. A 1.5-kb proximal PDGFR-b promoter containing a putative CSL-binding site
linked to a reporter gene was sufficient to mediate the N1ICD-induced transcriptional
response. A mutation of the element’s CSL-binding site resulted in significantly reduced
activation. Cells infected with adenoviral N1ICD were chromatin immunoprecipitated
with a N1ICD antibody. This analysis revealed an interaction between N1ICD and a part
of the PDGFR-b promoter containing the -256/249 CSL-binding site. Interestingly, the
same 1.5-kb PDGFR-b promoter element did not induce any response to N3ICD or to the
ligand-induced full-length NOTCH3 activation.
5.3 Reduced PDGFR-b expression in VSMC in Notch3-
deficient mice
For further analysis, mice with Notch3 interrupted by an insertion of lacZ (Notch3+/lacZ
and Notch3lacZ/lacZ) were generated and analysed for the expression patterns of PDGFR-b,
NOTCH3 (b-galactosidase) and some cell-specific markers. In cross-sections of the tails
of NotchlacZ/lacZ mice, an punctuated b-galactosidase expression was observed in cells
surrounding the lateral artery and vein. Both in the artery and the vein, b-galactosidase
expression co-localised with a-SMA immunostaining but not with the endothelial marker.
In the Notch3+/lacZ mouse artery, there was a significant co-distribution of PDGFR-b and
NOTCH3 immunoreactivity, and the PDGFR-b expression was reduced by 46% in the
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artery of a Notch3lacZ/lacZ mouse as compared to a Notch3+/lacZ mouse. The expression of
SMA was not significantly altered.
6 BLUNTED RESPONSE TO LIGAND INDUCED ACTIVATION
OF NOTCH IN CADASIL VSMCS
Endogenous NOTCH of the control and CADASIL VSMCs derived from the umbilical
cord were activated by immobilized JAGGED-1. The ligand activation induced a robust
increase in the PDGFR-b mRNA and protein expression in control VSMCs, whereas
CADASIL patients’ VSMCs, carrying the NOTCH3 p.Arg133Cys mutation, were
induced considerably less, both at the mRNA and protein level. In addition, a significant
difference was observed in the activation of the canonical NOTCH target genes. The
HEY1 and HES1 expressions were upregulated considerably more in the two control
VSMC lines (HEY1 10 and 9-fold; HES1 8 and 8.5-fold) than in CADASIL VSMCs
(HEY1 2.1-fold and HES1 2-fold). The ligand activation of NOTCH induced a blunted
upregulation of the PDGFR-b protein expression also in CADASIL VSMCs derived from
the adult’s systemic arteries (unpublished data).
7 CORRESPONDANCE OF NOTCH3 MUTATION AND GOM
The study cohort included 131 CADASIL patients with 33 different pathogenic
mutations. The presence of GOM and the NOTCH3 mutation was analysed in 80 patients
from France, and 51 patients from Finland and Sweden (belonging to 19 Finnish and 9
Swedish families). 26 different mutations were identified in the French families and 12 in
the Finnish and Swedish families. Of these mutations, three were previously unpublished
point mutations (p.Cys67Ser, p.Cys251Tyr and p.Tyr1069Cys) and one a novel
duplication (p.Glu434_Leu435dub) (Table 1 in Study IV). In Finland and Sweden, the
diagnostic molecular genetic analyses were originally limited to a restriction enzyme
analysis of two mutations previously found in Finland (p.Arg133Cys and p.Arg182Cys)
and in negative cases complemented by a sequence analysis of exons 3 and 4. Since the
electron microscopic analysis of the skin biopsies had shown presence of GOM in several
Finnish and Swedish suspected CADASIL patients with no detected mutation, an
extended genetic analysis for NOTCH3 was established. GOM was detected in the skin
biopsy of a Finnish patient, with a strong suspicion of CADASIL based on the clinical
picture and MRI findings, although no mutation was found even in the screening of the
NOTHC3 exons 2-24 using a selected set of 17 primers. GOM was also detected in a
biopsy of this patient’s sister with similar symptoms. This prompted a genetic analysis
with another set of primers, which revealed a heterozygous p.Gly528Cys mutation in both
patients. 26 CADASIL patients’ family members were analysed negative for the
NOTCH3 mutation.
GOM was detected in the skin biopsies of all the 131 patients, who in the genetic analysis
were also determined to carry a pathogenic NOTCH3 mutation. GOM was present above
all in arterial vessels, whereas the veins and capillaries were either GOM-negative or
seldom GOM-positive. In most of the cases, GOM was detected in the first biopsy, but in
a few cases repeated biopsy was needed since the first specimen was non-representative.
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Representative biopsies were negative for GOM in 26 subjects, who were also tested
negative for a NOTCH3 mutation that was detected in their relatives. In many GOM-
negative cases, cellular debris with a structure resembling GOM was detected between the
VSMCs.
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DISCUSSION
In this study, we have generated cultured VSMC lines from CADASIL patients and
healthy controls. These VSMCs are unique, and using these cell lines we have been able
to study the molecular pathogenesis of CADASIL at the cellular level. The results in this
study are concordant with the clinical findings and elucidate the molecular mechanisms
underlying the CADASIL pathology. However, most of the studies were conducted with
cell lines derived from patients and, therefore, we cannot completely rule out the
possibility that some of the differences between the cell lines may originate from genetic
variability. In addition, results from cell culture experiments should always be interpreted
with caution, since the natural environment of the cell is three-dimensional and includes
several nominators which cannot be mimicked in cell culture conditions.
1 PROTEIN MISFOLDING
1.1 Proteomic analysis
Our proteomic analysis is the first study on the CADASIL expression profile at either the
protein or RNA level
Protein degradation and folding
In the proteomic analysis, we identified altered expression levels of four proteins involved
in protein degradation and folding. Two of the identified proteins, proteasome beta chain
and component C3, were upregulated. They are T1A family peptidases and a part of the
20S core particle of the 26S proteasome multicatalytic proteinase complex (Nandi et al.
2006). Upregulation of the 20S proteasome complex proteins has been previously
reported in conjunction with several misfolding disorders (Bossy-Wetzel et al. 2004; Liu
et al. 2006), thus supporting the notion that the mutation in N3ECD causes misfolding of
the protein (Dichgans et al. 2000). Interestingly, the NOTCH3 N-terminal signal peptide
interacts with proteasome subunit alpha, and the presence of NOTCH3 in the cytosol
inhibits the proteasome activity (Zhang et al. 2007). In normal conditions, NOTCH3 is
not present in the cytosol, but may be in situations when misfolded proteins are
translocated from the ER for proteasomal degradation.
The other two proteins identified are heat shock protein 27 (HSP27) and ubiquitin
carboxy terminal hydrolase L1 (UCH-L1). HSP27 is a stress-inducible small heat shock
protein with a molecular chaperone activity. Molecular chaperones bind partially
denatured proteins, thereby preventing irreversible protein aggregation during stress.
HSP27 protects cells from, for example, a-synuclein-induced toxicity and aggregation
(Outeiro et al. 2006) and b-amyloid aggregation (Lee et al. 2006). Thus, in the CADASIL
VSMCs derived from the umbilical cord, the upregulated HSP27 may assist the mutated
NOTCH3 to fold correctly and become less prone to aggregation. HSP27 is a
multifunctional protein with numerous binding partners which is also involved in SMC
contraction and inhibition of apoptosis (Gerthoffer et al. 2001; Garrido et al. 1999).
UCH-L1 as a dimer has a ubiquitin-ligase activity and poly-ubiquitinates proteins through
the lysine 63 linkage (Liu et al. 2002), which is a signal for proteins to enter the
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endocytotic pathway rather than proteasomal degradation (Haglund et al. 2003). As a
monomer, it functions as a deubiquitilating enzyme (Liu et al. 2002; Wilkinson 1997).
UCH-L1 is downregulated in CADASIL VSMCs, and due to its dual role in
ubiquitination, downregulation may impair the poly-ubiquitination or deubiquitination
and thus impair either internalization or endosomal sorting (Haglund et al. 2003). A
mutation which impairs the activity of another ubiquitin ligase, Cbl, blocks the lysosomal
degradation of the EGF receptors and directs the receptors from the sorting endosomes to
the recycling pathway (Levkowitz et al. 1998). It is tempting to speculate that the UCH-
L1 may be involved in similar regulation to the ubiquitin ligase Cbl, marking the plasma
membrane receptors with ubiquitin for internalization, and at the same time sorting the
cargo for degradation, or if subsequently deubiquitylated, recycled to the plasma
membrane. If the misfolding of NOTCH3 causes a failure to be recognised by UCH-L1,
NOTCH3 would either remain attached to or become recycled into the plasma membrane.
In both cases this results in its accumulation on the VSMC surface (Joutel et al. 2000).
Cellular stress
Three proteins in the proteomic analysis, mitochodrial manganese superoxide dismutase
(MnSOD) (upregulated), glutathione S-transferase P1 (GST P1) (downregulated) and
glutathione S-transferase omega (GST omega) (downregulated), were identified as
proteins protecting cells from various toxic compounds. The MnSOD expression is
induced by reactive oxygen species (ROS), and it converts free radicals to oxygen and
hydrogen peroxide (Warner et al. 1996). The activity of MnSOD protects cells from free
radical damage, protein denaturation, and many other forms of progressive cell
degradation (Melov 2002). GST P1 and GST omega are cytosolic enzymes which are
involved in glutathione-mediated detoxification of a wide range of compounds, including
carcinogens, therapeutic drugs and products of oxidative stress. In addition, GSTs are
involved in the degradation of amino acids, synthesis of steroid hormones and important
metabolites of arachidonic acid, and they therefore have influence on many signalling
pathways of the cell (Hayes et al. 2005).
During the formation of disulphide bonds in the ER, electrons from thiol groups of the
substrate proteins are transferred to molecular oxygen by the ER oxidative folding
machinery (regulated by UPR), the process of which generates ROS as a by-product in
both the ER and mitochondria (Haynes et al. 2004; Tu et al. 2004). It has been suggested
that sulphur bridges which are improperly formed are reduced by glutathione, allowing
thiol groups to interact again with the proteins from the oxidative folding machinery. If
mutated proteins permanently fail to form the correct sulphur bridges, a futile cycling
between disulphide bonding and breakage will continue, and each cycle of the activating
ER oxidative folding machinery will generate ROS and consume glutathione. This can
lead to the depletion of glutathione and a further diminished ability of the cell to eliminate
increasingly-produced ROS (Haynes et al. 2004; Cuozzo et al. 1999). In CADASIL
VSMCs, where the mutated NOTCH3 fails to produce the correct sulphur bridges, the
downregulation of GSTs can be an indication of the exhaustion of cytosolic glutathione as
a result of repeated cycles of thiol group reduction and oxidation.
In addition, HSP27 that as a molecular chaperone promotes protein folding also protects
cells from various stress factors. Overexpression of HSP27 has been demonstrated to
increase the levels of glutathione, possibly by contributing to processes necessary for the
activity of enzymes that control glutathione reduction (Gerthoffer et al. 2001). The
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upregulation of MnSOD indicates increased mitochondrial ROS production, ER stress
and UPR activation (Warner et al. 1996; Haynes et al. 2004). This is consistent with the
observations that glutathione depletion results in mitochondrial dysfunction and ROS
accumulation (Merad-Boudia et al. 1998) and induces growth inhibition (Haynes et al.
2004). In keeping with this, our team has shown that mtDNA mutations are more frequent
in CADASIL patients (Annunen-Rasila et al. 2006), and the CADASIL VSMCs derived
from an umbilical cord used in this study have an impaired growth capacity.
The altered expression of proteins related to protein misfolding in cultured VSMCs of the
CADASIL patients suggest that the CADASIL VSMCs recognize unpaired thiol groups
and attempt to correct the improper sulphur bridging that cause protein misfolding.
Misfolded proteins are translocated from the ER to proteasomal degradation, which is
upregulated in response to increased demand. The consequent ER stress and activation of
UPR leads to increased ROS formation with subsequent upregulating of MnSOD as a
protective response, resultant glutathione depletion and inhibition of growth (Zhang et al.
2006; Haynes et al. 2004; Friedlander et al. 2000). However, UPR does not prevent
trafficking of misfolded NOTCH3 to the cell surface, though this trafficking has been
reported to be slowed (Karlstrom et al. 2002). The accumulation of N3ECD on the
surface of VSMCs could be further intensified by a failure in the recognition of mutated
N3ECD by UCH-L1, leading to impaired internalization or recycling of the receptor back
to the plasma membrane.
1.2 Expression and processing of NOTCH3
Immunocytochemical staining revealed that NOTCH3 forms more clusters and aggregates
on the surface of CADASIL VSMC cells compared to the control VSMCs. One
explanation for this could be that an unpaired cysteine residue in NOTCH3 forms sulphur
bridges with other unpaired cysteines in the neighbouring mutated NOTCH3 receptors or
with other proteins nearby. There have been several attempts in different cells expressing
transfected NOTCH3 to demonstrate whether the processing of the mutated NOTCH3 is
impaired or not, but the results have been inconsistent (Low et al. 2006; Joutel et al. 2004;
Peters et al. 2004; Karlstrom et al. 2002). In genetically genuine cultured VSMCs of the
CADASIL patients derived from the umbilical cord, placenta, or adult systemic and
cerebral arteries, the expression levels of NOTCH3 carrying a heterozygous or
homozygous p.Arg133Cys mutation were not significantly elevated when compared to
the corresponding control VSMCs. In addition, there was no significant processing
difference between the control and mutated NOTCH3 suggesting that the mutated
NOTCH3 is correctly S1-cleaved in the Golgi. No N3ECD accumulation on the cell
surface was detected in these cultured VSMCs probably due to the short accumulation
time (time between cell passages). This suggests that the accumulation of N3ECD in the
arteries is not due to the elevated NOTCH3 expression or impaired S1 processing but
rather because N3ECD clearance from the cell surface is impaired.
NOTCH3 expression is barely detectable in the VSMCs derived from the umbilical cord
and placenta. It is, however, substantially higher in VSMCs derived from the adult
systemic and cerebral subarachnoidal arteries, both in the CADASIL and control VSMCs.
This suggests that NOTCH3 is required to maintain arterial function in adults, and it may
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have a major role in vasoregulation in certain areas where its expression is high, for
example. in the brain
.
2 ALTERATIONS OF ACTIN FILAMENTS
2.1 Proteomic analysis
Proteomic analyses revealed an increased expression of four proteins, (1) the Rho protein
GDP-dissociation inhibitor (RhoGDI), (2) profilin 1, (3) HSP27 and (4) cysteine and
glycine-rich protein 1 (CRP1), which all interact with cytoskeletal proteins or are
involved in actin polymerization.
RhoGDI is a cytosolic regulator of Rho family GTPases (Grizot et al. 2001; Ueda et al.
1990; Ando et al. 1992; Leonard et al. 1992), and the amount of RhoGDI in a cell is
similar to the total amount of all Rho family GTPases (Michaelson et al. 2001).
Therefore, the upregulation of RhoGDI indicates an upregulation of the Rho family
GTPases and suggests enhanced signalling of the pathways regulated by them, including
VSMC contraction.
The most markedly upregulated protein in our analyses was profilin 1, which is a
regulatory protein of actin organization and is necessary for actin polymerization during
the contraction of SMC (Gutsche-Perelroizen et al. 1999; Tang et al. 2003). Profilin 1
enhances actin nucleation induced by Cdc42 via activation of WASp and Rho-mediated
actin filament assembly (Watanabe et al. 1999; Yang et al. 2000; Carlier et al. 1997).
VSMCs isolated from mice overexpressing profilin 1 have a higher expression level of
stress fibres, a significantly elevated F/G-actin ratio and increased Rho kinase expression.
In addition, these mice overexpressing profilin 1 have an elevated systolic blood pressure
and their aortic sections show structural changes with clear signs of medial hypertrophy.
These data indicate that overexpression of profilin 1 in VSMCs causes increased actin
polymerization and affects the VSMC function in vivo (Moustafa-Bayoumi et al. 2007).
The multifunctional HSP27 also interacts with the Rho family GTPases, such as the
signalling proteins Rho-associated coiled coil-containing protein kinase-II and RhoA.
Furthermore, it interacts with tropomyosin, stabilizes actin filaments, and plays a central
part in SMC contraction induced by agonists such as angiotensin II (Wang et al. 1998;
Somara et al. 2004; Patil et al. 2004). HSP27 acts as a capping protein binding to barbed
ends of F-actin. Upon agonist stimulation, it is phosphorylated by the MAPK pathway,
which leads to the dissociation of HSP27 from F-actin and allowing actin polymerization.
HSP27 also promotes focal adhesion stabilization (Gerthoffer et al. 2001).
CRP1 is specifically expressed in SMCs (Henderson 1999), and the CRP family members
have been shown to interact with two filamentous actin-binding proteins, ?-actinin
(Harper et al. 2000) and zyxin (Louis et al. 1997), which are important actin binding
proteins located at focal adhesions. It is interesting that most of the cytoskeletal proteins
identified in this study are involved in Rho GTPase family-mediated SMC contraction
and their expression is increased in CADASIL VSMCs derived from the umbilical cord.
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Interestingly, the RhoA activity and myosin heavy chain phosphorylation were decreased
in Notch3-/- mice, suggesting reduced actin polymerization (de Chantemele et al. 2008).
Since CADASIL VSMCs derived from the umbilical cord exhibit substantial upregulation
of several proteins interacting with actin and involved in SMC contraction, we analysed
the ability of these cells to contract in collagen-rich gels using a CGC assay. The results
were in direct contradiction to expectations: the relative collagen gel area was larger in
the CADASIL VSMC culture than in the control VSMC culture. This indicates that the
ability of the CADASIL VSMCs to contract spontaneously in collagen gels is markedly
diminished compared to the control cells, which may be caused by the rigidity of the actin
cytoskeleton in the CADASIL cells. Since in this CGC assay the cells were not exposed
to any contraction agonist, the question of the contractility of CADASIL VSMCs as a
response to agonists remains open.
2.2 Altered actin cytoskeletal organisation
The alterations of the actin cytoskeleton dynamics in the CADASIL VSMCs suggested by
the proteomic analysis and the CGC assay were supported by the immunocytochemical
studies on the actin cytoskeleton and adhesion complexes.
Cultured VSMCs of the CADASIL patients, isolated from the umbilical cord, placenta,
systemic and cerebral subarachnoidal arteries, exhibit altered actin filament organisation,
increased branching and organization problems. The severity of the alterations of actin
filament organisation was less manifest in VSMCs derived from the CADASIL patients’
umbilical cord and placenta, evident in VSMCs derived from arteries from adult tissues,
and the most severe in VSMCs derived from cerebral subarachnoidal arteries. These cells
also a exhibited differential morphology according to the tissue of origin: VSMCs from
cerebral subarachnoidal arteries exhibited a more epithelioid SMC-like phenotype,
whereas the other VSMC lines resembled a more spindle-shaped SMC phenotype (Li et
al. 2001). These two phenotypes have been shown to express SMC differentiation
markers and to respond to environmental stimuli differently (Li et al. 2001).
In CADASIL, the arteries in different cerebral areas are affected to a different degree, the
most affected vessels are small penetrating arteries in the cerebral white matter where the
majority of the lacunar infarcts also occur (Kalimo et al. 2008). This suggests that there is
a significant difference between the hemodynamic properties of the arteries even within
the same organ (Miao et al. 2004). For example, b-amyloid, the peptide which
accumulates in the amyloid plaques in Alzheimer disease, causes also amyloid angiopathy
and accumulates predominantly in cortical arteries. Furthermore, it was recently
demonstrated that in Notch3-/- mice the contractile activity of aorta is different from that
of cerebral arteries (Arboleda-Velasquez, et al. 2008). Therefore, it is not surprising that
VSMCs derived from the blood vessels of different organs are differentially affected in
the CADASIL patient VSMC lines. This suggests that VSMCs can have different
phenotypes, and the severity of the alterations in actin dynamics induced by mutated
NOTCH3 may be phenotype-specific and therefore, influence the vulnerability of the
arterial bed.
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The increased actin branching and node formation in CADASIL VSMCs suggests
increased activity of proteins inducing actin nucleation and branching, such as Arp2/3
complex, and inhibition of debranching proteins, such as cofilin or altered localization of
actin cross-linking proteins (Pollard, et al. 2003). This is supported by our proteomic
analysis, which showed increased expression of profilin, which is known to promote actin
nucleation. Profilin activates WASp, which in turn is an activator of the branching-
inducing Arp2/3 complex (Higgs et al. 2000). In addition, we detected upregulated
expression of RhoGDI that indicates increased expression of RhoGTPases, which in turn
causes activation of the kinase pathway leading to cofilin inactivation (Pollard 2003). The
severity of the alterations of actin filament structures correlates with NOTCH3 expression
levels. However, the alterations of actin filament structures are the strongest in the
VSMCs derived from cerebral arteries, even though the expression level of NOTCH3 is
not substantially higher when compared to the VSMCs derived from adult systemic
arteries. This may be related to the phenotypic differences between these cell lines and
suggests that cerebral arteries may have specific characteristics which amplify the effects
of the mutated NOTCH3, and may be the reason why the white matter arteries are
particularly prone to pathological alterations. Despite the differences in expression levels
of NOTCH3 and structural alterations in the actin cytoskeleton, there was no significant
difference in the total expression level of a-SMA between any of the cell lines.
The cultured VSMCs from CADASIL patients have altered adhesion complex
enlargement and arrangement. The adhesion complexes were abnormally distributed all
around the basolateral surface of the cells but had similar expression of talin, FAK and
cortactin as control VSMCs. Co-localization of FAK with vinculin suggests that these
structures have transformed from early focal complexes to focal adhesions and fibrillar
adhesions. Immunostaining for phosphotyrosine was similar in CADASIL and control
VSMCs suggesting that there are no substantial differences in kinase activity between
these cell lines and that the alterations in adhesion complex arrangement and enlargement
are initiated by the actin cytoskeletal changes. Integrin b5 representation was similar in
vinculin positive adhesion complexes in CADASIL and control VSMCs but integrin b1
was more localised with vinculin in control than in CADASIL VSMCs which may cause
differences in the adhesion properties.
Because the adhesion complexes in CADASIL VSMCs were smaller and distributed in
more central areas of the cells, we analysed the presence of tensin in these structures.
Tensin co-localised with vinculin in both CADASIL and control VSMCs, but in
CADASIL VSMCs the immunostaining for tensin was stronger as compared to control
cells suggesting higher expression level of tensin in CADASIL cells. In addition, integrin
b3 immunostaining localized into more central areas in the CADASIL cells as compared
to the control cells. These data suggest a switch in the balance of adhesion complexes
towards fibrillar adhesions in CADASIL VSMCs.
Furthermore, western blot analysis showed increased expression of vinculin in CADASIL
VSMCs as compared to corresponding control cells. Concordantly with this, our
proteomic study showed upregulation of three actin-binding or associated proteins that
localise to adhesion complexes, i.e. profilin 1, HSP27 and CRP 1. Changes in the
adhesion complex enlargement may possibly alter the integrins’ affinity/avidity to the
ECM. This is supported by the observation that the CADASIL VSMCs are attached to the
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culture surface more tightly than the control VSMCs. Furthermore, VSMCs of tg
NOTCH3R90C mice exhibit cytoskeletal changes in the form of the presence of more and
thicker dense plaques, (Ruchoux et al. 2003; Monet et al. 2007). The adhesion problems
can also be morphologically detected in the patients’ arteries, where the subendothelial
space is enlarged and the VSMCs lose their intercellular connections before any extensive
degeneration of the VSMCs has occurred (Ruchoux et al. 1997). This might be due to
alterations in actin polymerization and structures, and altered force development, which
cause changes in the formation of the adhesion complexes (dense plaques) and altered
integrin affinity/avidity, all initiated by the mutated NOTCH3 function.
2.3 Conclusion on altered actin organisation
It has been demonstrated that the expression of constitutively active N3ICD leads to an
increase of actin stress fibres and higher steady-state levels of polymerized actin
(Domenga et al. 2004). On the other hand, the Notch3-/- mice have an increased
vasodilation response to shear stress, a reduced vascular tone induced by mechanical
strain, decreased RhoA activity and myosin heavy chain phosphorylation suggesting
decreased actin polymerization (de Chantemele et al. 2008). These data indicate that
NOTCH3 promotes actin polymerization and is involved in mechanical strain response. It
has therefore been suggested that NOTCH3 may serve as a sensor that provides the
VSMCs with an ability to rearrange actin in response to mechanical strain (Domenga et
al. 2004). On the other hand, the tg NOTCH3R90C mice were demonstrated to have
increased pressure-induced myogenic tone and decreased vasodilation induced by shear
stress, acetoazolamide and hypercapnia (Lacombe et al. 2005; Dubroca et al. 2005) as
compared to the wild-type littermates, thus suggesting an increased NOTCH3 activity. In
addition, the retinal arterioles of the CADASIL patients appear similarly contracted to
those in hypertensive patients (Roine et al. 2006). Our proteomic data show upregulation
of four proteins associated with the actin cytoskeleton, which suggests increased actin
polymerization in the CADASIL VSMCs. Our immunocytochemical stainings for actin
cytoskeleton demonstrate that in some CADASIL patients, the VSMCs exhibit altered
actin filament organization, for example, increased branching. However, in some
CADASIL VSMC lines actin polymerization was impaired, which would rather agree
with decreased NOTCH3 signalling. Further studies are needed to clarify these somewhat
discrepant results. In culture conditions, cells are not exposed to shear stress or cyclic
strain and therefore, the signals stimulating actin polymerization and enlargement of
adhesion complexes are different from the in vivo situation; therefore, these results have
to be interpreted with care. Our data indicate that a mutation in NOTCH3 causes
impairments in the regulation of actin dynamics, adhesion comples assembly and cell
adhesion. The variation of the severity of these impairments may depend on the NOTCH3
expression level and the VSMC phenotypes in different vascular beds.
3 ANTI-APOPTOSIS
A bioinformatic evaluation of the data from the proteomic analyses resulted in the
classification of the identified proteins into functional categories according to the
information in on-line databases (Table 1). Interestingly, through this analysis three
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upregulated proteins, HSP27, RhoGDI and GST P1, were linked to anti-apoptotic
signalling. HSP27 inhibits cytocrome c-dependent activation of procaspase 9 (Garrido et
al. 1999) and thereby prevents apoptosis. In addition, over-expression of RhoGDI
decreases activated c-Jun N-terminal kinase (JNK) expression (Park et al. 2008), and GST
P1 inhibits the activity of the same protein and thus both increase cell viability and inhibit
apoptosis (Townsend et al. 2003). Apoptosis has been demonstrated in CADASIL patient
lymphocytes, fibroblasts, endothelial cells, pericytes, neurons and glial cells but not in the
VSMCs (Gray et al. 2007; Formichi et al. 2008). Previously reported findings that
NOTCH3 promotes survival and protects VSMCs from apoptosis have been performed in
vitro (Wang et al. 2002; Sweeney et al. 2004). Upregulation of anti-apoptotic proteins in
CADASIL VSMCs may reflect protective responses against apoptosis, the mechanisms of
which are still unresolved in CADASIL patients.
4 PDGFR-b UPREGULATION IS BLUNTED IN CADASIL VSMCS
We identified a novel cross-talk between PDGFR-b and NOTCH, in which activation of
NOTCH resulted in the upregulation of PDGFR-b expression (Study III). This regulation
was inhibited in CSL-/- embryonic stem cells, indicating that the regulation was mediated
by NICD-CSL interaction. The PDGFR-b expression was increased in response to
N1ICD and N3ICD expression, but, interestingly, the mechanism of upregulation was
different: N1ICD, but not N3ICD, activated PDGFR-b reporter gene expression from a
CSL binding site 1.5 kb proximal to the PRGFR-b promoter. Both NOTCH receptors
require the presence of CSL to mediate upregulation. This suggests that NOTCH3
signalling upregulates PDGFR-b expression using an alternative CSL-binding site located
outside the 1.5-kb promoter element. This is consistent with the finding that different
NICDs have different target sequence selectivity (Ong et al. 2006) and suggests that
different NOTCH receptors have distinct functional missions.
NOTCH induced an increase in the PDGFR-? protein expression, and the proportionally
augmented intracellular PDGF response. The dynamic interplay between NOTCH and
PDGF signalling may also be important for the control of VSMC cell migration because
the migration-promoting capacity of PDGF-BB was found to be restrained by a NOTCH-
induced inhibition of VSMC migration, consistent with an earlier study (Campos et al.
2002). This finding is in line with our results on alterations in CADASIL patients’ VSMC
actin cytoskeleton, an important player in VSMC motility.
PDGFR-? expression was demonstrated to be reduced in VSMCs in the lateral tail arteries
of newborn Notch3lacZ/lacZ mice, in the cells showing an aberrant phenotype of the Notch3-
/- mice. Therefore, given the importance of PDGF signalling for VSMC recruitment and
differentiation in arteries, it is tempting to speculate that the reduced PDGFR-? expression
contributes to the observed phenotype. This notion is supported by the observation that
the reduction in PDGFR-? expression takes place well before the morphological changes
are observed. It is also of note that the reduction of PDGFR-? expression is observed
specifically in the cells which, in the Notch3 wild type mouse, have active NOTCH3
signalling (Monet et al. 2007). Interestingly, it was recently demonstrated that cyclic
strain induces PDGFR-b phosphorylation in a ligand-independent manner and leads to
VSMC marker gene expression in embryonic stem cells (Shimizu et al. 2008). These
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observations, combined with the reduction of PDGFR-? upregulation in Notch3-deficient
cells in response to NOTCH activation, further support an important role for NOTCH3 in
regulation of PDGFR-? expression.
We demonstrated that the VSMCs of CADASIL patients with the p.Arg133Cys mutation
exhibit a reduced upregulation of PDGFR-? (mRNA and protein), HES1 (mRNA), and
HEY1 (mRNA) expression in response to ligand activation. The upregulation of the target
genes was not due to an impaired g-secretase cleavage since equal amounts of N3ICD
were detected from un-activated CADASIL and control VSMCs. This is intriguing, since
NOTCH3 has been shown to induce normal canonical signalling despite any mutations
(Haritunians et al. 2002; Low et al. 2006; Joutel et al. 2004; Peters et al. 2004; Karlstrom
et al. 2002; Monet et al. 2007), and the CADASIL pathology is suggested to originate
from an impairment of a yet unknown NOTCH3-regulated pathway. Reduced activation
of the canonical NOTCH3 target genes, HES1 and HEY1, in cultured CADASIL VSMCs
indicates that in culture conditions, VSMCs cannot compensate for the impaired
NOTCH3 function and that in vivo, such compensatory mechanisms exist or they are cell
type or animal species-specific. On the other hand, the experimental setting may not
generate effective NOTCH activation. In this experiment, the ligand was attached to the
culture plate surface. If the mobility of the VSMCs to be activated was diminished due to
the rigidity of the actin cytoskeleton, it could possibly reduce the pulling force needed for
the dissociation of the NECD, and thus impair receptor activation.
PDGFR-b is involved in actin organization, which we showed to be altered in the VSMCs
of CADASIL patients. PDGFR-b interacts with the Na+/H+ exchanger regulatory factor
(NHERF), which is a multifunctional adapter protein that binds merlin and the ERM
family (MERM) of membrane-cytoskeletal linker proteins. The MERM family proteins
provide a link between the membrane and the cortical actin cytoskeleton, and participate
in Rho/Rac family GTPase-mediated signalling pathways (James et al. 2004). PDGFR-b,
with a C-terminal point mutation that abolishes NHERF-binding displays defects in
integrin-mediated spreading and migration, and exhibits altered F-actin rearrangement and
focal adhesion formation when compared to cells expressing the wild type receptor
(James et al. 2004). These similarities to our observations in CADASIL VSMCs suggest
the possibility that the CADASIL pathology might at least partly be caused by impaired
regulation of the PDGFR-b expression by NOTCH3. However, it is an open issue
whether expression of other NOTCH receptors can substitute for the NOTCH3 receptor in
regulation of the PDGFR-? expression in VSMCs in vivo.
5 GOM AS A DIAGNOSTIC TOOL
Suspicion of CADASIL is based on the clinical picture, characteristic MRI findings and a
suggestive family history (O'Sullivan et al. 2001). A definitive diagnosis is made by
analysing the NOTCH3 gene and detecting a pathogenic mutation. Due to the large
number of mutations causing CADASIL (Supplemental Table in Study IV) and the large
size of the NOCTH3 gene, comprehensive analysis of all potentially affected exons is
time-consuming and costly. The EM detection of GOM from skin biopsy has been
considered highly specific, but the sensitivity has been disputable (Markus et al. 2002;
Ebke et al. 1997; Mayer et al. 1999; Razvi et al. 2003). In our patients, detection of GOM
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from skin biopsy was a highly reliable method in the diagnostic work-up of the suspected
CADASIL patients. GOM was detected in the skin biopsy of all 131 patients, in whom
the NOTCH3 mutation had been identified and from whom a representative skin biopsy
was available. Thus, the congruence was 100%. This study was performed
retrospectively, and therefore, to exclude possible selection bias a prospective study is
required to obtain an exact figure for the sensitivity, which we estimate to be well over
90%.
In Finland, the genetic analysis of the Finnish and Swedish patients was originally
restricted to two mutations previously found in Finland/Sweden, complemented by the
sequence analysis of exons 3 and 4. The EM analysis was at first used mainly to support
the genetic testing, but it was also particularly used in cases where the clinical suspicion
was very strong but the result of the limited genetic testing was negative. The finding of
several such GOM-positive and NOTCH3 mutation-negative cases prompted us to screen
all the exons with known pathogenic mutations, i.e. NOTCH3 exons 2-24, which led to
the detection of four novel, previously unpublished, mutations (Study IV) and, in
addition, seven mutations previously undiagnosed in Finland/Sweden (unpublished
results). In one Finnish patient with a GOM-positive skin biopsy, the NOTCH3 mutation
was not detected until the analysis was performed with another set of primers (at Hôpital
Lariboisière, the most experienced diagnostic molecular genetic CADASIL laboratory),
thus demonstrating that there are also caveats in sequencing. This experience further
emphasizes the sensitivity and value of skin biopsy examinations as a guide for more
comprehensive genetic analyses, and asserts the sensitivity of EM detection of GOM from
skin biopsy.
In the EM analysis of GOM from skin biopsies, special attention should be paid to the
quality of the technical processing and analysis of the skin biopsy. The vessels in which
GOM is best detectable are generally medium-sized or small arterioles (outer diameter
generally 20-40 µm) in deep dermis or upper subcutis. The examination should preferably
be targeted at an artery (with multiple layers of VSMCs and an inner elastic lamina)
rather than a vein or a capillary, since these vessels are not always GOM-positive in
CADASIL patients. The osmium tetroxide treatment should be adjusted so that the GOM
becomes sufficiently well contrasted. Furthermore, if GOM is not found in the first vessel
investigated, other vessels or even repeat biopsies should be examined. A prerequisite is,
of course, that GOM is recognized correctly and distinguished from fallacious deposits.
The ultrastructural resolution and characteristic appearance of GOM most likely make the
EM analysis more reliable than immunohistochemical detection of accumulated N3ECD
(Joutel et al. 2001), especially in younger patients with small amounts of accumulated
N3ECD. GOM can be detected even in patients below the age of 20 years, whereas
nonspecific staining is an inherent caveat of immunohistochemistry (Lesnik Oberstein et
al. 2003). Moreover, the EM examination also provides information about other
pathological changes in the arterial wall, such as those due to hypertension, ageing and
possibly even other hereditary arteriopathies (Ruchoux et al. 2002; Ruchoux et al. 2000;
Brulin et al. 2002).
Just recently, another cerebral small vessel disease was identified, which is caused by a
novel type of pathogenic mutation in exon 25 (p.Leu1515>Pro) of NOTCH3 outside the
domain with EGF repeats, causing increased canonical NOTCH3 signalling in a ligand-
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independent fashion (Fouillade et al. 2008). Remarkably, in this single patient reported so
far, there is no deposition of N3ECD or GOM on VSMCs.
The most efficient strategy to confirm the clinical suspicion of CADASIL strongly
depends on the patient’s family history and the mutational background in the population
to which the suspected patient belongs. Since mutation screening covering the whole
region coding for EGF repeats (exons 2-24) is not realistic for all patients and for most
laboratories, in families with a known mutation or populations with major mutations the
diagnostic work-up is best begun by first searching for those mutations. If there is no
known founder mutation or other determined mutation, screening of the mutational hot
spot region of the NOTCH3 gene should be the method of choice. Of all the reported
pathogenic NOTCH3 mutations, 62% locate in exons 3, 4, 5 and 8. Furthermore, to obtain
an 80% coverage, an additional investigation of exons 2, 6, 11 and 18 is required
(Supplemental Table in Study IV). At the latest after these analyses, an EM examination
for the detection of GOM is highly recommended.
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CONCLUSIONS
I) In a proteomic analysis of VSMCs derived from an umbilical cord of
CADASIL baby and healthy controls, we identified differentially expressed
proteins, which suggests that mutated NOTCH3 causes ER stress, activates
UPR and leads to increased production of ROS. CADASIL VSMCs have
altered actin dynamics mediated by RhoGTPases, which suggests an increased
NOTCH3 function.
II) A mutation in NOTCH3 causes alterations in actin cytoskeletal structures,
increased branching, and abnormal node formation in VSMCs, and these
changes correlate with the NOTCH3 expression level. This suggests that
phenotypic differences of SMCs may affect the vulnerability of the VSMCs;
therefore mutated NOTCH3 may influence arteries of different vascular beds
differently.
III) PDGFR-b is an immediate downstream target gene of NOTCH3 signalling,
and this regulation is impaired in CADASIL VSMCs; thus, it may serve as a
molecular mechanism leading to CADASIL pathology.
IV) The strategy of the CADASIL diagnostic work-up should be based on logical
evaluation of clinical findings, family history, and use of both the genetic and
morphological methods available. In cases in which genetic analysis is not
available or the mutation is difficult to identify, a skin biopsy is easy to
perform and, in experienced hands, EM is a highly reliable diagnostic method.
Importantly, it is invaluable in guiding how far one should proceed with the
genetic analyses.
Figure 6. A hypothesis for molecular mechanisms involved in CADASIL pathology. (A) Free
cysteine residues in the mutated NOTCH3 can serve as a sticky interaction surface, which may lead to
receptor activation even in response to weak stimulation. In addition to the canonical DSL ligands,
ECM proteins, MAGP 1 and 2, can serve as ligands for NOTCH3. Mechanical strain induces binding of
MAGP 1 and 2 to NOTCH3, which leads to dissociation of N3ECD from the receptor, thereby initiating
signalling. N3ECD is not degraded but accumulates on and around VSMCs. (B) N3ICD enters the
nucleus and initiates the expression of target genes, such as. PDGFR-b. (C) On the plasma membrane,
PDGFR-b can be activated by mechanical stretching or by binding of an agonist, both of which lead to
autophosphorylation and activation of intracellular signalling cascades, including RhoGTPases and the
MAPK pathway. (D) RhoGTPases interact with profilin and FAK, and promote actin polymerization.
(E) Activation of the MAPK pathway leads to phosphorylation of Hsp27, causing dissociation of this
protein from the barbed end of an actin filament and promoting actin polymerization. (F) MAPK
activates the LIM kinase (LIMK) leading to phosphorylation of cofilin, which dissociates from actin,
thereby reducing its depolymerisation and debranching. (G) PDGFR-b is also linked to the cytoskeleton
and focal adhesions through the adapters NHERF, MERM and FAK. An altered PDGFR-b expression
can lead to impairment of actin and focal adhesion dynamics. (H) Direct interaction of N3ICD with
integrins is altered, and the avidity of integrins to ECM is changed, which induces altered actin
dynamics. (I) Interactions of N3ICD and TGF-b-signalling proteins, smads, are altered, leading to
increased TGF-b activity, which induces fibrosis. Proteins identified in this study are represented with
symbols in colour, and other proteins associated with them in grey scale. PM = plasma membrane.
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